

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF OHIO
EASTERN DIVISION**

**IN RE: NATIONAL PRESCRIPTION
OPIATE LITIGATION**

THIS DOCUMENT RELATES TO:

*The County of Summit, Ohio, et al. v.
Purdue Pharma L.P., et al.,
Case No. 18-op-45090*

MDL No. 2804

Case No. 1:17-md-2804

Judge Dan Aaron Polster

*The County of Cuyahoga, Ohio, et al. v.
Purdue Pharma L.P., et al.,
Case No. 17-op-45004*

WALGREENS' TRIAL EXHIBIT LIST

Defendants Walgreen Co. and Walgreen Eastern Co. ("Walgreens") hereby submit their individual trial exhibit list, pursuant to the Civil Jury Trial Order, ECF No. 1598, as amended on July 29, 2019, and as set forth in the Parties' Joint Trial Exhibit Stipulation and Template submitted to the Court on August 16, 2019.

Walgreens submits this list subject to all of the rights reserved in the Parties' Joint Trial Exhibit Stipulation and in the Defendants' Joint Trial Exhibit List filed today.

Dated: September 25, 2019

Respectfully submitted,

/s/ Kaspar J. Stoffelmayr
Kaspar J. Stoffelmayr
Brian C. Swanson
Katherine M. Swift
Matthew W. Brewer
BARTLIT BECK LLP
54 West Hubbard Street
Chicago, IL 60654
Phone: (312) 494-4400
Fax: (312) 494-4440
Email: kaspar.stoffelmayr@bartlitbeck.com
Email: brian.swanson@bartlitbeck.com
Email: kate.swift@bartlitbeck.com
Email: matthew.brewer@bartlitbeck.com

Alex J. Harris
BARTLIT BECK LLP
1801 Wewatta Street, 12th Floor
Denver, CO 80202
Phone: (303) 592-3100
Fax: (303) 592-3140
Email: alex.harris@bartlitbeck.com

Counsel for Walgreen Co. and Walgreen Eastern Co.

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Not Offered Admitted Admitted		
WAG-0001	4/24/1971	21 CFR 1301.01 - Registration of Manufacturers, Distributors, and Dispensers of Controlled Substances Security Requirements, General Information	WAGMDL_T1_TX00000055	WAGMDL_T1_TX00000055							
WAG-0002	9/21/1971	Title 21 CFR Part 1301.72 Physical Security Control for Non-Practitioners; Narcotic Treatment Programs and Compounders for Narcotic Treatment Programs; Storage Areas.		WAGMDL_T1_TX00000056	WAGMDL_T1_TX00000058						
WAG-0003	00/00/1982	Dark Paradise: A History of Opiate Addiction in America, David T. Courtwright									
WAG-0004	12/27/1988	Letter from R. Buzzeto to Walgreen Co. re Proposed System of Detecting and Reporting Excessive Orders	US-DEA-00025683	US-DEA-00025683							
WAG-0005	02/00/1990	Chronic Opioid Therapy in Nonmalignant Pain by R. Portenoy, Journal of Pain and Symptom Management	WAGMDL00766273	WAGMDL00766291							
WAG-0006	5/18/1993	DEA Diversion Investigators Manual, FOIA Confidential Treatment Requested by Cardinal	CAH_MDL_PRIORPROD_DE A07_01176247-R	CAH_MDL_PRIORPROD_DE A07_01176558-R							
WAG-0007	04/00/1994	The need for an open mind about the treatment of chronic nonmalignant pain by M. Reidenberg et al, Clinical Pharmacology & Therapeutics	WAGMDL00766292	WAGMDL00766296							
WAG-0008	00/00/1995	Executive Summary, Institute of Medicine (US) Committee on Federal Regulation of Methadone Treatment by R. Retting et al, National Academies	WAGMDL_T1_TX00000059	WAGMDL_T1_TX00000070							
WAG-0009	00/00/1995	State Laws and Regulations, Institute of Medicine (US) Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Development of Medications for the Treatment of Opiate and Cocaine Addictions by C. Fulco et al, National Academies Press	WAGMDL_T1_TX00000071	WAGMDL_T1_TX00000079							
WAG-0010	08/00/1997	DOJ ARCOS Registrant Handbook, Office of Diversion and Control	WAGMDL_T1_TX00000080	WAGMDL_T1_TX00000270							
WAG-0011	08/00/1997	ARCOS Registrant Handbook	WAGMDL00282651	WAGMDL00282841							
WAG-0012	02/00/1999	Report to the U.S. Attorney General by the Suspicious Orders Task Force and Supplemental Report to the Attorney General									
WAG-0013	10/00/2000	Pain as the 5th Vital Sign Toolkit	WAGMDL_T1_TX00000271	WAGMDL_T1_TX00000327							
WAG-0014	11/27/2000	Form 10-K for the fiscal year ended August 31, 2000, Walgreen Co	WAGMDL_T1_TX00000328	WAGMDL_T1_TX00000344							
WAG-0015	01/00/2001	DOJ Chemical Handler's Manual, A Guide to Chemical Control Regulation	WAGMDL00395965	WAGMDL00396033							
WAG-0016	5/17/2001	Hearings Before a Subcommittee of the Committee on Appropriations House of Representatives 107th Congress; Subcommittee on the Departments of Commerce, Justice, and State, the Judiciary, and Related Agencies Appropriations for 2002									
WAG-0017	7/29/2001	The Alchemy of Oxycontin, The New York Times:	WAGMDL_T1_TX00000345	WAGMDL_T1_TX00000354							
WAG-0018	8/28/2001	OxyContin : Its Use and Abuse, hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, First Session									
WAG-0019	00/00/2003	Responsible Prescribing of Opioids for the Management of Chronic Pain by B. Nicholson	WAGMDL_T1_TX00000355	WAGMDL_T1_TX00000356							
WAG-0020	00/00/2003	Chronic Non-Malignant Musculoskeletal Pain in Older Adults: Clinical Issues and Opioid Intervention by V. K. Podichetty et al, Postgrad Med J	WAGMDL_T1_TX00000357	WAGMDL_T1_TX00000363							
WAG-0021	00/00/2003	Drug Enforcement Administration History 1999-2003	WAGMDL_T1_TX00000364	WAGMDL_T1_TX00000391							
WAG-0022	12/00/2003	GAO Report to Congressional Requesters - Prescription Drugs, OxyContin Abuse and Diversion and Efforts to Address the Problem									
WAG-0023	11/9/2004	Form 10-K for the fiscal year ended August 31, 2004, Walgreen Co	WAGMDL_T1_TX00000392	WAGMDL_T1_TX00000405							
WAG-0024	11/30/2004	Controlled Drug Policy	WAGFLDEA00000020	WAGFLDEA00000020							
WAG-0025	00/00/2005	Microeconometrics Methods and Applications by A. C. Cameron et al,	WAGMDL_T1_TX00000406	WAGMDL_T1_TX00001463							
WAG-0026	1/18/2005	Federal Register Solicitation on Comments on Dispensing Controlled Substances for Treatment of Pain (Resp't Ex. 002-A)	WAGMDL00766050	WAGMDL00766051							
WAG-0027	2/15/2005	Handling Suspicious Drug Orders	WAGFLDEA00001854	WAGFLDEA00001855							
WAG-0028	2/25/2005	Comment of M. Fleming, AAFP to K. Tandy, DEA re Solicitation of Comments on Dispensing Controlled Substances (Resp't Ex. 002-D)	WAGMDL00766057	WAGMDL00766058							
WAG-0029	2/28/2005	Follow the Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain, Kaiser Family Foundation	WAGMDL_T1_TX00001464	WAGMDL_T1_TX00001497							
WAG-0030	3/21/2005	Comment of AMA and ASA, "Solicitation of Comments on Dispensing of Controlled Substances for the Treatment of Pain" (Resp't Ex. 002-B)	WAGMDL00766052	WAGMDL00766053							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Not Offered Admitted Admitted		
WAG-0031	3/21/2005	Comment of J. Orient, AAPS letter to DEA Deputy Administrator re Docket No. DEA-261N (Resp't Ex. 002-C)	WAGMDL00766054	WAGMDL00766056							
WAG-0032	3/21/2005	Comments of Washington Legal Foundation to the DEA re Dispensing of Pain Medications (Resp't Ex. 002-F)	WAGMDL00766072	WAGMDL00766075							
WAG-0033	8/12/2005	Email from K. Wright to S. Mays re Internet Pharmacy Presentation	US-DEA-00003880	US-DEA-00003881							
WAG-0034	10/20/2005	Memorandum from M. Mapes to J. Rannazzisi re Internet Presentation with McKesson Corp. on September 1, 2005	MCKMDL00496859	MCKMDL00496875							
WAG-0035	10/21/2005	Federal Register Controlled Substances Proposed Aggregate Production Quotas for 2006 (Resp't Ex. 004)	WAGMDL00766076	WAGMDL00766079							
WAG-0036	10/24/2005	Pharmacies Endorse Crackdown on Fraud, The New York Times:	WAGMDL_T1_TX00001498	WAGMDL_T1_TX00001499							
WAG-0037	12/9/2005	Federal Register Controlled Substances Established Initial Aggregate Production Quotas for 2006 (Resp't Ex. 004)	WAGMDL00766080	WAGMDL00766083							
WAG-0038	3/30/2006	DEA Congressional Testimony, M. Braun re Counternarcotics Strategies in Latin America	WAGMDL_T1_TX00001500	WAGMDL_T1_TX00001505							
WAG-0039	5/17/2006	Letter from DOJ R. Corso to Walgreens T. Polarolo re Regulatory Investigation	WAGMDL00709510	WAGMDL00709512							
WAG-0040	5/17/2006	Letter from R. Corso to T. Polarolo re March 2006 DEA Regulatory Investigation of Walgreens	WAGMDL00753477	WAGMDL00753479							
WAG-0041	5/27/2006	Memorandum from T. Polarolo to J. Joseph re DEA Audit Preliminary Response 03-06-06	WAGMDL00709508	WAGMDL00709509							
WAG-0042	7/5/2006	Federal Register Controlled Substances Proposed Revised Aggregate Production Quotas for 2006 (Resp't Ex. 004)	WAGMDL00766084	WAGMDL00766086							
WAG-0043	7/28/2006	Letter from D. Pinon to DEA B. Dobric re Walgreens Distribution Center, Perrysburg, Ohio	WAGMDL00387642	WAGMDL00387650							
WAG-0044	8/16/2006	Feds bust major heroin ring, Chicago Tribune									
WAG-0045	8/29/2006	Federal Register Controlled Substances Proposed Aggregate Production Quotas for 2007 (Resp't Ex. 004)	WAGMDL00766091	WAGMDL00766094							
WAG-0046	10/19/2006	Federal Register Controlled Substances Final Revised Aggregate Production Quotas for 2006 (Resp't Ex. 004)	WAGMDL00766087	WAGMDL00766090							
WAG-0047	11/9/2006	Top stores to close by John Booth, Crain's Cleveland Business:									
WAG-0048	12/11/2006	Rx Questionable Order Qty, Mt. Vernon Distribution Center	WAGMDL00757788	WAGMDL00757788							
WAG-0049	12/11/2006	Federal Register Controlled Substances Established Initial Aggregate Production Quotas for 2007 (Resp't Ex. 004)	WAGMDL00766095	WAGMDL00766098							
WAG-0050	00/00/2007	Responsible Opioid Prescribing, A Physician's Guide by S. Fishman	WAGMDL00766312	WAGMDL00766329							
WAG-0051	2/7/2007	Good Faith Practices and Fraudulent Prescriptions	WAGMDL00008112	WAGMDL00008113							
WAG-0052	3/28/2007	Good Faith Practices and Fraudulent Prescriptions	WAGMDL00008110	WAGMDL00008111							
WAG-0053	4/3/2007	Email from M. Soliva to J. VanOverbake re DEA Suspicious Controlled Drug Report	WAGMDL00400357	WAGMDL00400357							
WAG-0054	4/25/2007	Letter from McKesson Counsel, Hyman, Phelps, & McNamara, P.C., to L. Barber DEA re Order to Show Cause Pending Against McKesson	MCKMDL00330924	MCKMDL00330930							
WAG-0055	05/00/2007	Long-term Use of Controlled-release Oxycodone for Noncancer Pain: Results of a 3-year Registry Study by R. Portenoy et al, Clinical Journal of Pain	WAGMDL00766297	WAGMDL00766311							
WAG-0056	5/3/2007	Federal Register Controlled Substances Proposed Revised Aggregate Production Quotas for 2007 (Resp't Ex. 004)	WAGMDL00766099	WAGMDL00766102							
WAG-0057	6/12/2007	Letter from J. Gilbert, McKesson Counsel, to L. Barber re McKesson's Implementation of Lifestyle Drug Monitoring Program	MCKMDL00330931	MCKMDL00330964							
WAG-0058	7/3/2007	Southwood Pharmaceuticals, Inc. Revocation of Registration, Federal Register Notice	WAGMDL_T1_TX00001506	WAGMDL_T1_TX00001540							
WAG-0059	7/27/2007	Internal Audit Report Memo from L. Dettmer et al to R. Varno et al re DEA Compliance Review - Jupiter Distribution Center	WAGMDL00757549	WAGMDL00757568							
WAG-0060	8/24/2007	Federal Register Controlled Substances Final Revised Aggregate Production Quotas for 2007 (Resp't Ex. 004)	WAGMDL00766103	WAGMDL00766106							
WAG-0061	8/24/2007	Federal Register Controlled Substances Proposed Aggregate Production Quotas for 2008 (Resp't Ex. 004)	WAGMDL00766107	WAGMDL00766110							
WAG-0062	9/11/2007	Office of Diversion Control website print out, 13th Pharmaceutical Industry Conference, Houston Texas, September 11-12, 2007	CAH_MDL_PRIORPROD_DE A12_00011059	CAH_MDL_PRIORPROD_DE A12_00011063							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Not Offered Admitted Admitted		
WAG-0063	11/9/2007	BuzzoPDMA's 5th Annual Controlled Substance Conference, Cegedim Dendrite Slide Deck	ALLERGAN_MDL_03755273	ALLERGAN_MDL_03755424							
WAG-0064	12/3/2007	Walgreen Suspicious Control Drug Orders for Month of 11/2007	WAGMDL00390035	WAGMDL00390036							
WAG-0065	12/27/2007	Federal Register Controlled Substances Established Initial Aggregate Production Quotas for 2008 (Resp't Ex. 004)	WAGMDL00766111	WAGMDL00766113							
WAG-0066	00/00/2008	Drug Enforcement Administration History 2003-2008	WAGMDL_T1_TX00001541	WAGMDL_T1_TX00001576							
WAG-0067	1/1/2008	Prescription Opioid Use, Misuse, and Diversion Among Street Drug Users in New York City by W. Davis et al, Drug Alcohol Depend	WAGMDL_T1_TX00001577	WAGMDL_T1_TX00001593							
WAG-0068	2/22/2008	Internal Audit Report Memo from T. Bennett et al to J. Coman et al re DEA Compliance Review - Woodland Distribution Center	WAGMDL00757511	WAGMDL00757513							
WAG-0069	3/26/2008	Email from D. Pinon to L. Sullivan re Suspicious Order Reporting	WAGMDL00387651	WAGMDL00387652							
WAG-0070	4/30/2008	Walgreens Records Retention Schedule	WAGMDL00286244	WAGMDL00286424							
WAG-0071	6/23/2008	Memo from W. Bancroft et al to S. Bamberg et al re DEA Suspicious Order Reporting	WAGMDL00624503	WAGMDL00624509							
WAG-0072	6/23/2008	Memo from W. Bancroft and T. Morris to S. Bamberg re DEA Suspicious Order Reporting	WAGMDL00624503	WAGMDL00624509							
WAG-0073	6/23/2008	Memo from W. Bancroft and T. Morris to S. Bamberg re DEA Suspicious Order Reporting	WAGMDL00624527	WAGMDL00624532							
WAG-0074	7/1/2008	Federal Register Controlled Substances Proposed Revised Aggregate Production Quotas for 2008 (Resp't Ex. 004)	WAGMDL00766114	WAGMDL00766116							
WAG-0075	7/28/2008	Internal Audit Report Memo from T. Bennett et al to C. Johnson et al re DEA Compliance - Mt. Vernon Distribution Center	WAGMDL00757569	WAGMDL00757570							
WAG-0076	10/6/2008	Walgreen Suspicious Control Drug Orders for Month of 09/2008	WAGMDL00390720	WAGMDL00390721							
WAG-0077	10/6/2008	Walgreen Suspicious Control Drug Orders for Month of 09/2008	WAGMDL00390757	WAGMDL00390758							
WAG-0078	10/17/2008	Letter from W. Goggin to J. Gray re Controlled Substances Ac	WAGMDL00673706	WAGMDL00673722							
WAG-0079	11/7/2008	Federal Register Controlled Substances Proposed Aggregate Production Quotas for 2009 (Resp't Ex. 004)	WAGMDL00766121	WAGMDL00766124							
WAG-0080	11/12/2008	Federal Register Controlled Substances Final Revised Aggregate Production Quotas for 2008 (Resp't Ex. 004)	WAGMDL00766117	WAGMDL00766120							
WAG-0081	12/22/2008	Internal Audit Report Memo from L. Dettmer et al to S. Kneller et al re DEA Compliance - Perrysburg Distribution Center	WAGMDL00757193	WAGMDL00757211							
WAG-0082	12/29/2008	Federal Register Controlled Substances Established Initial Aggregate Production Quotas for 2009 (Resp't Ex. 004)	WAGMDL00766125	WAGMDL00766129							
WAG-0083	00/00/2009	Quantitative Techniques for Competition and Antitrust excerpt	WAGMDL_T1_TX00001594	WAGMDL_T1_TX00001594							
WAG-0084	00/00/2009	Introductory Econometrics, A Modern Approach by J. Wooldridge, South-Western Cengage Learning	WAGMDL_T1_TX00001595	WAGMDL_T1_TX00002480							
WAG-0085	00/00/2009	FY 2009 Performance Budget, DEA Congressional Budget Submissior	WAGMDL_T1_TX00002481	WAGMDL_T1_TX00002628							
WAG-0086	02/00/2009	Walgreens Controlled Substance Threshold Requirements Documen	WAGMDL00491896	WAGMDL00491912							
WAG-0087	02/00/2009	Walgreens Controlled Substance Threshold Requirements Documen	WAGMDL00492132	WAGMDL00492149							
WAG-0088	02/00/2009	Walgreens Controlled Substance Threshold Requirements Documen	WAGMDL00492626	WAGMDL00492639							
WAG-0089	02/00/2009	Intercepted/Suspicious Orders	WAGMDL00658202	WAGMDL00658216							
WAG-0090	02/00/2009	Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain by R. Chou et al, The Journal of Pain	WAGMDL00766635	WAGMDL00766674							
WAG-0091	3/27/2009	Email from J. Lalich to T. Morris re Revised Suspicious Order Document	WAGMDL00325368; WAGMDL00325374	WAGMDL00325368; WAGMDL00325378							
WAG-0092	5/21/2009	Federal Register Controlled Substances Proposed Aggregate Production Quotas for 2009 (Resp't Ex. 004)	WAGMDL00766139	WAGMDL00766142							
WAG-0093	6/1/2009	P09002 Threshold Controlled Substance Macro Design	WAGMDL00491961	WAGMDL00491966							
WAG-0094	6/3/2009	P09002 Threshold Controlled Substance Ordering Driver Program	WAGMDL00491998	WAGMDL00492000							
WAG-0095	6/25/2009	Letter from R. Corso to Kneller re DEA On-Site Investigation	WAGMDL00493683	WAGMDL00493687							
WAG-0096	7/2/2009	A History of Vicodin, New York Magazine	WAGMDL_T1_TX00002629	WAGMDL_T1_TX00002631							
WAG-0097	7/6/2009	Walgreen Suspicious Control Drug Orders for Month of 06/2009	WAGMDL00392428	WAGMDL00392429							
WAG-0098	7/23/2009	Federal Register Controlled Substances Proposed Revised Aggregate Production Quotas for 2009 (Resp't Ex. 004)	WAGMDL00766130	WAGMDL00766134							
WAG-0099	7/28/2009	Akron Police Department Incident Report re D. Richards and T. Warc	AKRON_001158027	AKRON_001158028							
WAG-0100	7/28/2009	Akron Police Department Report of Investigation re T. Ward and D. Richard:	AKRON_001225698	AKRON_001225702							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0101	7/28/2009	Letter from S. Kneller to R. Corso re June 25, 2009 Correspondence	WAGMDL00493688	WAGMDL00493691							
WAG-0102	8/21/2009	Martin B Threshold Violations	WAGMDL00674560	WAGMDL00674560							
WAG-0103	8/25/2009	MartinB Order Item Detail	WAGMDL00674550	WAGMDL00674550							
WAG-0104	8/25/2009	Order Item Detail Reports	WAGMDL00674550	WAGMDL00674623							
WAG-0105	8/25/2009	Martin B Order Item Detail	WAGMDL00674550	WAGMDL00674550							
WAG-0106	8/25/2009	Martin B Order Item Detail	WAGMDL00674551	WAGMDL00674551							
WAG-0107	8/25/2009	Corpsup Weekly Item Movement Detai	WAGMDL00674552	WAGMDL00674552							
WAG-0108	8/25/2009	Martin B Order Item Detail	WAGMDL00674553	WAGMDL00674553							
WAG-0109	8/25/2009	Corpsup Weekly Item Movement Detai	WAGMDL00674554	WAGMDL00674554							
WAG-0110	8/25/2009	Martin B Order Item Detail	WAGMDL00674555	WAGMDL00674555							
WAG-0111	8/25/2009	Corpsup Weekly Item Movement Detai	WAGMDL00674556	WAGMDL00674556							
WAG-0112	8/25/2009	Martin B Order Item Detail	WAGMDL00674557	WAGMDL00674557							
WAG-0113	8/25/2009	Martin B Order Item Detail	WAGMDL00674558	WAGMDL00674558							
WAG-0114	8/25/2009	Corpsup Weekly Item Movement Detai	WAGMDL00674559	WAGMDL00674559							
WAG-0115	8/25/2009	Corpsup Weekly Item Movement Detai	WAGMDL00674561	WAGMDL00674561							
WAG-0116	8/25/2009	Corpsup Weekly Item Movement Detai	WAGMDL00674622	WAGMDL00674622							
WAG-0117	8/25/2009	Martin B Threshold Violations	WAGMDL00674623	WAGMDL00674623							
WAG-0118	8/26/2009	Project Request Estimate	WAGMDL00492067	WAGMDL00492069							
WAG-0119	8/28/2009	Memo from B. Martin re Suspicious Ordering Pilot	WAGMDL00658227	WAGMDL00658227							
WAG-0120	8/28/2009	Email from M. Bleser to D. Murray et al re November 8th DEA Meeting at	WAGMDL00658246	WAGMDL00658248							
WAG-0121	9/23/2009	Martin B Threshold Violations	WAGMDL00674619	WAGMDL00674619							
WAG-0122	9/23/2009	Martin B Threshold Violations	WAGMDL00674620	WAGMDL00674620							
WAG-0123	9/23/2009	Martin B Threshold Violations	WAGMDL00674621	WAGMDL00674621							
WAG-0124	9/25/2009	P09002 Threshold Controlled Substance Macro Design II	WAGMDL00492038	WAGMDL00492043							
WAG-0125	10/1/2009	Project Request Estimate	WAGMDL00492070	WAGMDL00492072							
		Walgreens Controlled Substance Threshold Requirements Document - Project P09002	WAGMDL00491878	WAGMDL00491895							
WAG-0126	10/2/2009										
WAG-0127	10/21/2009	Federal Register Controlled Substances Final Revised Aggregate Production Quotas for 2009 (Resp't Ex. 004)	WAGMDL00766135	WAGMDL00766138							
WAG-0128	10/21/2009	Federal Register Controlled Substances Established Initial Aggregate Production Quotas for 2010 (Resp't Ex. 004)	WAGMDL00766143	WAGMDL00766146							
WAG-0129	00/00/2010	Prescription Drug Abuse & Diversion: Role of the Pain Clinic by K. Rigg et al, J Drug Issues									
WAG-0130	1/5/2010	M. Ranick letter to DEA Miami Field Division re Walgreens Jupiter Distribution Center (Resp't Ex. 259-E)	WAGMDL00655723	WAGMDL00655738							
WAG-0131	1/20/2010	P09002 Intercept Suspicious Orders Micro Design - ORPB305	WAGMDL00492076	WAGMDL00492081							
WAG-0132	2/17/2010	Ranick Threshold Violations Detai	WAGMDL00674576	WAGMDL00674594							
WAG-0133	2/17/2010	Ranick Threshold Violations Detai	WAGMDL00674595	WAGMDL00674614							
WAG-0134	3/1/2010	Walgreen Suspicious Control Drug Orders for Month of 02/2010	WAGMDL00393114	WAGMDL00393115							
WAG-0135	3/9/2010	DEA Phase II Project Implementation Plan	WAGMDL00492130	WAGMDL00492131							
WAG-0136	3/11/2010	LOSSPRV Weekly Item Movemen!	WAGMDL00674615	WAGMDL00674616							
WAG-0137	3/11/2010	Ranick Order Item Detail	WAGMDL00674617	WAGMDL00674618							
WAG-0138	05/00/2010	VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain	WAGMDL00766675	WAGMDL00766833							
WAG-0139	5/25/2010	Tolerance Limit Calculations	WAGMDL00128847	WAGMDL00128850							
WAG-0140	5/25/2010	Walgreens Tolerance Limit Calculation:	WAGMDL00491847	WAGMDL00491850							
WAG-0141	5/25/2010	Walgreens Ordering Frequency Calculation:	WAGMDL00491851	WAGMDL00491853							
WAG-0142	6/7/2010	Walgreen Suspicious Control Drug Orders for Month of 05/2010	WAGMDL00393581	WAGMDL00393582							
WAG-0143	6/23/2010	Federal Register Controlled Substances Proposed Revised Aggregate Production Quotas for 2010 (Resp't Ex. 004)	WAGMDL00766147	WAGMDL00766150							
WAG-0144	7/6/2010	Walgreen Suspicious Control Drug Orders for Month of 06/2010	WAGMDL00393621	WAGMDL00393623							
WAG-0145	7/10/2010	Email from S. Wedekind to A. Parlato re Oxycodone 30 mg	WAGFLDEA00000459	WAGFLDEA00000460							
WAG-0146	7/19/2010	Email from Pharmacy Manager 11423 to District247rx re Forgery	WAGFLDEA00000360	WAGFLDEA00000360							
WAG-0147	7/27/2010	J. Wright email to T. Gubbins re Handling Pain Management RX	WAGFLDEA00000659	WAGFLDEA00000660							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0148	8/2/2010	T. Gubbins email to Market3RXSupv, Market28RXSupv re Oxycodone Sale:	WAGFLDEA00000812	WAGFLDEA00000823							
WAG-0149	8/6/2010	S. Raval email to District 109RX re RXM Meeting Oxycodone	WAGFLDEA00000363	WAGFLDEA00000364							
WAG-0150	8/18/2010	Ranick Order Item Detail	WAGMDL00674562	WAGMDL00674575							
WAG-0151	8/27/2010	Email from N. Reboco to N. Baran et al re Oxycodone Order:	ALLERGAN_MDL_02879229	ALLERGAN_MDL_02879230							
WAG-0152	8/28/2010	R. Lemke email to District114Stores@Walgreens re District Notes and Focus Points	WAGFLDEA00000828	WAGFLDEA00000828							
WAG-0153	9/8/2010	Email from B. Martin to D. Coughlin re Mt. Vernon DEA Audi	WAGMDL00387641	WAGMDL00387641							
WAG-0154	9/14/2010	S. Raval email to District 109RX re Two Minute Oxy-Refusal Consul	WAGFLDEA00000368	WAGFLDEA00000369							
WAG-0155	9/14/2010	Federal Register Controlled Substances Final Revised Aggregate Production Quotas for 2010 (Resp't Ex. 004)	WAGMDL00766151	WAGMDL00766154							
WAG-0156	9/15/2010	Federal Register Controlled Substances Final Revised Aggregate Production Quotas for 2011 (Resp't Ex. 004)	WAGMDL00766155	WAGMDL00766158							
WAG-0157	10/20/2010	Federal Register Controlled Substances Established Initial Aggregate Production Quotas for 2011 (Resp't Ex. 004)	WAGMDL00766159	WAGMDL00766162							
WAG-0158	10/21/2010	Email from E. Svihra to K. Amos et al re Margate, FL Schedule II Limitations (Svihra)	WAGFLDEA00000829	WAGFLDEA00000832							
WAG-0159	11/1/2010	Email from K. Amos to D. Lemmons et al re Margate, FL Schedule II Limitations (Lemmons)	WAGFLDEA00000833	WAGFLDEA00000841							
WAG-0160	12/6/2010	Walgreen Suspicious Control Drug Orders for Month of 11/2010	WAGMDL00394459	WAGMDL00394460							
WAG-0161	12/16/2010	S. Vazquez email to District21RX re Schedule II Controlled Substance:	WAGFLDEA00000435	WAGFLDEA00000435							
WAG-0162	12/28/2010	Akron Police Department Report of Investigation re L. Lee	AKRON_001227427	AKRON_001227430							
WAG-0163	00/00/2011	Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse in the United States by H. Birnbaum et al, Pain Medicine - Forensic Pain Medicine Section	WAGMDL_T1_TX00002632	WAGMDL_T1_TX00002642							
WAG-0164	00/00/2011	Store 3099 - Refusals to Fill	WAGMDL00767135	WAGMDL00768833							
WAG-0165	1/10/2011	Email from B. Martin to K. Atwell re High Quality Stores 682971	WAGFLDEA00000846	WAGFLDEA00000851							
WAG-0166	1/11/2011	Email from B. Martin to K. Atwell re High Quality Stores 682971	WAGFLDEA00000852	WAGFLDEA00000862							
WAG-0167	1/17/2011	Email from D. Lemmons to K. Amos et al re CII Fills-Ft. Pierce	WAGFLDEA00000863	WAGFLDEA00000864							
WAG-0168	1/28/2011	Email from E. Svihra to D. Lemmons et al re Rx Numbers - Oviedo FL (Svihra)	WAGFLDEA00000885	WAGFLDEA00000886							
WAG-0169	2/6/2011	Email from C. Dymon to T. Polster et al re Order Inquiry - Store 1160C	WAGMDL00096071	WAGMDL00096074							
WAG-0170	2/7/2011	Email from E. Svihra to M. Ranick re Stop SORs	WAGMDL00387624	WAGMDL00387624							
WAG-0171	2/9/2011	Email from E. Svihra to E. Stahmann re Oviedo FL (Stahmann	WAGFLDEA00000887	WAGFLDEA00000889							
WAG-0172	2/11/2011	Email from E. Stahmann to E. Lanzetti et al re Oviedo FI	WAGFLDEA00000890	WAGFLDEA00000890							
WAG-0173	2/23/2011	Good Faith Practices and Fraudulent Prescriptions, Redline against 3/23/07	WAGMDL00767015	WAGMDL00767019							
WAG-0174	3/2/2011	Guide re Refilling Prescriptions	WAGFLDEA00000271	WAGFLDEA00000271							
WAG-0175	3/2/2011	B. Wheeldon email to S. Corley re 3099 Oxycodone Issue	WAGFLDEA00000902	WAGFLDEA00000903							
WAG-0176	3/4/2011	B. Martin email to K. Atwell re INC000002834005	WAGFLDEA00000908	WAGFLDEA00000911							
WAG-0177	3/9/2011	Action Plan to Reduce CII Dispensing re Store 1412	WAGFLDEA00000912	WAGFLDEA00000912							
WAG-0178	3/25/2011	Email from B. Wheeldon to T. Gubbins et al re CII Prescription:	WAGFLDEA00000999	WAGFLDEA00001006							
WAG-0179	3/25/2011	B. Wheeldon email to T. Gubbins re Pharmacist Best Price:	WAGFLDEA00000661	WAGFLDEA00000693							
WAG-0180	3/25/2011	B. Wheeldon email to E. Svihra re Best Practices Conf Cal	WAGFLDEA00000988	WAGFLDEA00000988							
WAG-0181	3/28/2011	B. Wheeldon email to D. Lemmons re Store 3099	WAGFLDEA00001009	WAGFLDEA00001010							
WAG-0182	04/00/2011	Economic Costs of Nonmedical Use of Prescription Opioids by R. Hansen et al, Clinical Journal of Pain	WAGMDL_T1_TX00002643	WAGMDL_T1_TX00002651							
WAG-0183	4/12/2011	Suggested Questions a Distributor Should Ask Prior to Shipping Controlled Substances	WAGMDL00387638	WAGMDL00387640							
WAG-0184	4/12/2011	Suggested Questions a Distributor Should Ask Prior to Shipping Controlled Substances	WAGMDL00387638	WAGMDL00387640							
WAG-0185	4/29/2011	Email from Pharmacy Manager 04402 to S. Vazquez re Oxycodone	WAGFLDEA00000438	WAGFLDEA00000438							
WAG-0186	05/00/2011	The prescription drug epidemic in the United States: A perfect storm, Carlisle Maxwell, Drug & Alcohol Review	WAGMDL_T1_TX00002652	WAGMDL_T1_TX00002658							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0187	05/00/2011	Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours, B. Larance et al., Drug & Alcohol Review	WAGMDL_T1_TX00002659	WAGMDL_T1_TX00002668							
WAG-0188	5/6/2011	Walgreens Pharmacy and Health Care Code of Conduct and General Training	WAGFLDEA00000127	WAGFLDEA00000130							
WAG-0189	5/11/2011	Email from M. Gill to T. Trumbull et al re VAWD Question	WAGMDL00751821	WAGMDL00751823							
WAG-0190	5/11/2011	Email from M. Gill to T. Trumbull re VAWD Question	WAGMDL00751821	WAGMDL00751823							
WAG-0191	5/16/2011	Claimant's Request for Production of Documents to Plaintiff, Supplemental Response to Request No. 9	HDS_MDL_00002032	HDS_MDL_00002045							
WAG-0192	5/17/2011	B. Martin email to K. Atwell re CII Order	WAGFLDEA00001060	WAGFLDEA00001076							
WAG-0193	5/24/2011	Statement for the Record of M. Leonhart re Responding to the Prescription Drug Epidemic: Strategies for Reducing Abuse, Misuse, Diversion, and Fraud	WAGMDL_T1_TX00002669	WAGMDL_T1_TX00002681							
WAG-0194	5/31/2011	Email from G. Couffer to Market6LPS et al re Su Florida June Focus on Compliance - Filing Pain Management Prescriptions (Florida Markets Only)	DOJ_0017111	DOJ_0017116							
WAG-0195	5/31/2011	G. Couffen email to Market6LPS, Market28LPS, Market3LPS re Florida June Focus on Compliance	WAGFLDEA00001704	WAGFLDEA00001709							
WAG-0196	6/14/2011	W. Rohn email to District 12RX, District 112MGR re Roxy tricks	WAGFLDEA00000374	WAGFLDEA00000375							
WAG-0197	6/20/2011	Controlled Substance Prescriptions & Good Faith Dispensing Policy	WAGMDL00008104	WAGMDL00008105							
WAG-0198	6/20/2011	Controlled Substance Prescriptions & Good Faith Dispensing Policy	WAGMDL00767020	WAGMDL00767021							
WAG-0199	6/20/2011	Controlled Substance Prescriptions & Good Faith Dispensing Policy, Redline against 2/23/11	WAGMDL00767022	WAGMDL00767027							
WAG-0200	7/1/2011	Email from D. Lemmons to D. Pinon et al re Florida HB 7095 - July 1, 2011	WAGFLDEA00001081	WAGFLDEA00001086							
WAG-0201	7/5/2011	Walgreen Suspicious Control Drug Orders for Month of 06/2011	WAGMDL00395016	WAGMDL00395017							
WAG-0202	7/5/2011	Walgreen Suspicious Control Drug Orders for Month of 06/2011	WAGMDL00395106	WAGMDL00395107							
WAG-0203	7/5/2011	Walgreen Suspicious Control Drug Orders for Month of 06/2011	WAGMDL00395124	WAGMDL00395125							
WAG-0204	7/11/2011	Email from E. Svihra to K. Amos re Florida Focus on Compliance - Long	WAGFLDEA00001141	WAGFLDEA00001144							
WAG-0205	7/17/2011	Controlled Substance Prescriptions & Good Faith Dispensing Policy	WAGMDL00008102	WAGMDL00008103							
WAG-0206	7/17/2011	Controlled Substance Prescriptions & Good Faith Dispensing Policy, Redline against 6/20/11	WAGMDL00767028	WAGMDL00767030							
WAG-0207	7/18/2011	RX Mail email to All Pharmacies re Controlled Substance Prescriptions and Good Faith Dispensing Policy Update	WAGFLDEA00000388	WAGFLDEA00000388							
WAG-0208	7/20/2011	Email from D. Lemmons to E. Lanzetti et al re Florida Focus on Compliance	WAGFLDEA00000696	WAGFLDEA00000740							
WAG-0209	7/20/2011	T. Isbon email to District100RX, 100MGR, 100Stores re Oxycodone Dispensing	WAGFLDEA00001154	WAGFLDEA00001155							
WAG-0210	7/20/2011	E. Svihra email to E. Lanzetti re The Uniqueness of Florida	WAGFLDEA00001158	WAGFLDEA00001159							
WAG-0211	8/10/2011	Email from A. Spiehs to B. Wheeldon re Medicaid Fraud - Please Reac	WAGFLDEA00001160	WAGFLDEA00001160							
WAG-0212	8/17/2011	The DEA Opines on Corresponding Responsibility of Pharmacists, Pharmacy Jurisprudence	WAGMDL00766972	WAGMDL00766988							
WAG-0213	8/23/2011	A. Moothedan memo to S. Corley re District 227 Oxycodone Action Plan	WAGFLDEA00001174	WAGFLDEA00001175							
WAG-0214	8/24/2011	A. Spiehs email to B. Wheeldon re Customer Confrontation with Employee	WAGFLDEA00001176	WAGFLDEA00001176							
WAG-0215	8/26/2011	Email from Pharmacy Manager 05857 to A. Spiehs re Oxy	WAGFLDEA00000443	WAGFLDEA00000443							
WAG-0216	8/26/2011	A. Moothedan email to B. Wheeldon re 5857 Oxy Threat	WAGFLDEA00001209	WAGFLDEA00001209							
WAG-0217	9/7/2011	M. Rakauskas email to M. Rakauskas re Controlled Substance Best Practices Update	WAGFLDEA00000396	WAGFLDEA00000397							
WAG-0218	9/14/2011	Federal Register Controlled Substances Proposed Aggregate Production Quotas for 2011 (Resp't Ex. 004)	WAGMDL00766163	WAGMDL00766167							
WAG-0219	9/18/2011	Email from Pharmacy Manager 12885 to J. Donovan et al re Question/Advice - Sorry Long Read	WAGFLDEA00000401	WAGFLDEA00000401							
WAG-0220	9/21/2011	CII-CV Controlled Substances Mini Audit for Jupiter DC, Audit Period June 11 - Aug 11	WAGFLDEA00001796	WAGFLDEA00001811							
WAG-0221	9/23/2011	DEA Suspicious Order - Phase III	WAGMDL00492378	WAGMDL00492380							
WAG-0222	9/28/2011	M. McLaughlin email to Pharmacy Manager 02941 re Oxycodone	WAGFLDEA00000416	WAGFLDEA00000416							
WAG-0223	9/30/2011	Guide re Accepting and Filling New Prescriptions Policy	WAGFLDEA00000445	WAGFLDEA00000446							
WAG-0224	10/8/2011	K. Kratofil email to District119RX re Oxy Scripts and Referral:	WAGFLDEA00000465	WAGFLDEA00000465							
WAG-0225	10/13/2011	Store Manager 03099 email to K. Kratofil re Dr. Yankopolis	WAGFLDEA00000466	WAGFLDEA00000466							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0226	10/18/2011	Email from G. Lehoczky to Market6Rx et al re Market Action Plan/Guidelines for CII Dispensing	WAGFLDEA00000741	WAGFLDEA00000762							
WAG-0227	10/18/2011	G. Lehoczky email to Market6RX re Market Action Plan	WAGFLDEA00001211	WAGFLDEA00001212							
WAG-0228	10/21/2011	Federal Register Controlled Substances Proposed Aggregate Production Quotas for 2012 (Resp't Ex. 004)	WAGMDL00766172	WAGMDL00766175							
WAG-0229	10/25/2011	H. Morrow email to B. Wheeldon re DEA Red Flags:	WAGFLDEA00001219	WAGFLDEA00001220							
WAG-0230	10/25/2011	H. Morrow email to B. Wheeldon re Save the date MGR RXM Mtg with the DEA Dec 7, 2011	WAGFLDEA00001221	WAGFLDEA00001221							
WAG-0231	10/28/2011	R. Espino email to B. Wheeldon re Police Security	WAGFLDEA00000449	WAGFLDEA00000449							
WAG-0232	10/31/2011	Letter from Maddox Horne Law Firm, PLLC to Walgreens re Dr. Raymond Failer - Refusal to Fill	WAGMDL00768918	WAGMDL00768918							
WAG-0233	11/00/2011	Health Care Guideline: Assessment and Management of Chronic Pain, Institute for Clinical Systems Improvement	WAGMDL00766834	WAGMDL00766946							
WAG-0234	11/1/2011	Update on Federal Controlled Substance Dispensing Responsibilities by D. Brushwood, Power-Pak C.E.	WAGMDL00766989	WAGMDL00767008							
WAG-0235	11/4/2011	Control Substances and Good Faith Dispensing, Walgreens Policy	WAGFLDEA00000471	WAGFLDEA00000475							
WAG-0236	11/4/2011	K. Kratofil email to Mgr. 06775 re Control Substance Powerpoint from Wednesday	WAGFLDEA00000477	WAGFLDEA00000507							
WAG-0237	11/8/2011	Controlled Substance Prescriptions & Good Faith Dispensing	WAGFLDEA00000206	WAGFLDEA00000207							
WAG-0238	11/8/2011	Controlled Substance Prescriptions & Good Faith Dispensing Policy	WAGMDL00008100	WAGMDL00008101							
WAG-0239	11/8/2011	Controlled Substance Prescriptions & Good Faith Dispensing Policy, Redline against 7/17/11	WAGMDL00767031	WAGMDL00767033							
WAG-0240	11/18/2011	Email from D. Healy to T. Fernandez re Dr. Stark Meeting	WAGFLDEA00000763	WAGFLDEA00000765							
WAG-0241	11/30/2011	E. Svihra email to B. Wheeldon re Patients' Notice for Pain Management	WAGFLDEA00001274	WAGFLDEA00001276							
WAG-0242	12/2/2011	T. Gubbins email to Market3RXSupv re Background to share with stores on CI	WAGFLDEA00000426	WAGFLDEA00000427							
WAG-0243	12/3/2011	R. Espino email to B. Wheeldon re Urgent Do not Fax the DEA	WAGFLDEA00001280	WAGFLDEA00001281							
WAG-0244	12/5/2011	Email from K. Kratofil to B. Wheeldon et al re Possible Media Attention from CVS AIWs	WAGFLDEA00001282	WAGFLDEA00001287							
WAG-0245	12/5/2011	Walgreen Suspicious Control Drug Orders for Month of 11/2011	WAGMDL00395713	WAGMDL00395714							
WAG-0246	12/5/2011	Walgreen Suspicious Control Drug Orders for Month of 11/2011	WAGMDL00395729	WAGMDL00395730							
WAG-0247	12/5/2011	Walgreen Suspicious Control Drug Orders for Month of 11/2011	WAGMDL00395745	WAGMDL00395746							
WAG-0248	12/7/2011	Email from G. Lehoczky to E. Forbes et al re Oxy Percen	WAGFLDEA00001288	WAGFLDEA00001327							
WAG-0249	12/7/2011	Email from K. Kratofil to D. Pinon re Meeting Questions/MISC	WAGFLDEA00001331	WAGFLDEA00001332							
WAG-0250	12/7/2011	Control Drug Shipments by Item Report and CII-CV Controlled Substances Minimum Audit for Jupiter DC, Audit Period Sep 11 - Nov 11	WAGFLDEA00001812	WAGFLDEA00001829							
WAG-0251	12/9/2011	Federal Register Controlled Substances Final Adjusted Aggregate Production Quotas for 2011 (Resp't Ex. 004)	WAGMDL00766168	WAGMDL00766171							
WAG-0252	12/15/2011	B. Wheeldon email to T. Gubbins re Fear over Oxycodon	WAGFLDEA00001333	WAGFLDEA00001333							
WAG-0253	12/15/2011	Federal Register Controlled Substances Established Aggregate Production Quotas for 2012 (Resp't Ex. 004)	WAGMDL00766176	WAGMDL00766179							
WAG-0254	12/15/2011	Letter from B. Newman to K. Kratofil re Lee County Medical Solutions, Inc. - Refusal to Fill	WAGMDL00768916	WAGMDL00768917							
WAG-0255	12/17/2011	K. Kratofil email to T. Gubbins re Refusal to Fill Verbiag	WAGFLDEA00001337	WAGFLDEA00001338							
WAG-0256	00/00/2012	Collection of Emails re Controlled Substance Orders	WAGMDL00757172	WAGMDL00757187							
WAG-0257	00/00/2012	DEA FY 2012 Performance Budget Congressional Submission									
WAG-0258	00/00/2012	Navigating the Management of Chronic Pain: A Pharmacist's Guide by K Jackson et al, Power-Pak C.E.	WAGMDL00766955	WAGMDL00766971							
WAG-0259	00/00/2012	Sample of Suspicious Orders	WAGMDL00767044	WAGMDL00767067							
WAG-0260	00/00/2012	Chart re Number of FL DEA Notification Webforms Submitted Aug. 2012 and Sept. 2012	WAGMDL00767068	WAGMDL00767134							
WAG-0261	01/00/2012	DEA Update Powerpoint	WAGMDL00707642	WAGMDL00707653							
WAG-0262	1/16/2012	Letter from K. Myrick to R. Giacalone, Cardinal Health re FOI/PA Request re Diversion Investigators Manual	CAH_MDL2804_02203353	CAH_MDL2804_02203357							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0263	1/18/2012	Email from M. Rakauskas to A. Hoheisel re Controlled Substance Guideline	WAGFLDEA00001348	WAGFLDEA00001348							
WAG-0264	1/18/2013	Email from C. Dymon to P. Daugherty re SOM Process Flow Document	WAGMDL00237698	WAGMDL00237702							
WAG-0265	1/18/2013	In re Walgreen Co. - Respondents' Consolidated Prehearing Statement in the Pharmacy Matters (USDOJ-DEA)	WAGMDL_T1_TX00002682	WAGMDL_T1_TX00002732							
WAG-0266	1/22/2012	K. Kratofil email to District119RX, District119MGR re New Fax Number for the DEA	WAGFLDEA00000516	WAGFLDEA00000516							
WAG-0267	1/24/2012	E. Svihra email to D. Lemmons re Florida Pain Medications	WAGFLDEA00001375	WAGFLDEA00001378							
WAG-0268	1/24/2012	B. Wheeldon email to T. Gubbins re Florida Pain Medication	WAGFLDEA00001390	WAGFLDEA00001393							
WAG-0269	1/26/2012	E. Lanzetti email to E. Svihra re Customers using intimidation to get scripts filled	WAGFLDEA00001403	WAGFLDEA00001411							
WAG-0270	1/30/2012	Florida Law Enforcement Prescription Drug Efforts Produce Positive Results, Purchases of Oxycodone Decline, DEA Press Release	WAGMDL00766622	WAGMDL00766623							
WAG-0271	2/6/2012	Walgreen Suspicious Control Drug Orders for Month of 01/2012	WAGMDL00395803	WAGMDL00395804							
WAG-0272	2/8/2012	Email from B. Martin to D. Murray re Suspicious Order Monitoring Process	WAGMDL00325129	WAGMDL00325130							
WAG-0273	2/8/2012	Suspicious Order Monitoring Process	WAGMDL00325128	WAGMDL00325128							
WAG-0274	2/13/2012	Walgreens Tolerance Limit Calculation	WAGMDL00492393	WAGMDL00492396							
WAG-0275	2/20/2012	Controlled Substance Monitoring Business Requirements	WAGMDL00108983	WAGMDL00109002							
WAG-0276	2/22/2012	Email from L. Merten to E. Svihra et al re EJS Reply: Florida Controlled Substances	WAGFLDEA00001498	WAGFLDEA00001505							
WAG-0277	2/23/2012	Email from E. Forbes to B. Smith et al re Florida - Controlled Substance	WAGFLDEA00001511	WAGFLDEA00001513							
WAG-0278	2/5/2012	M. Hutchens email to M. Polzin re Two CVS Pharmacies Raided in DEA pill	WAGFLDEA00001425	WAGFLDEA00001427							
WAG-0279	2/26/2012	Email from D. Lemmons to E. Svihra et al re C2	WAGFLDEA00001518	WAGFLDEA00001523							
WAG-0280	3/1/2012	E. Svihra email to K. Amos re Florida Trip Best Practices and Comment	WAGFLDEA00001538	WAGFLDEA00001541							
			DOJ 0015362; DOJ 0015382; DOJ 0015394; DOJ 0015399; DOJ 0015400; DOJ 0015407; DOJ 0015410; DOJ 0015414	DOJ 0015371; DOJ 0015384; DOJ 0015394; DOJ 0015400; DOJ 0015410; DOJ 0015416							
WAG-0281	3/5/2012	Email from H. Morrow to Walgreens Consumer Relations re Dissatisfied, Walgreens Issue Communication Form	WAGFLDEA00000522	WAGFLDEA00000566							
WAG-0282	3/5/2012	H. Morrow email to Consumerrelations.bb@walgreens.com re Ref #3606291 dissatisfied	WAGFLDEA00000567	WAGFLDEA00000607							
WAG-0283	3/7/2012	New Front Opens in Florida Pill War by T. Martin et al, The Wall Street Journal	WAGMDL00766626	WAGMDL00766627							
WAG-0284	3/15/2012	Controlled Substances and List I Chemical Registration and Reregistration Fees, DEA Rule, Federal Register Webpage Printout	WAGMDL_T1_TX00002733	WAGMDL_T1_TX00002769							
WAG-0285	3/15/2012	W. Burdick email to H. Morrow re Ref #3614575	WAGFLDEA00000567	WAGFLDEA00000607							
WAG-0286	3/19/2012	E. Forbes email to D. Lemmons re DEA Conference	WAGFLDEA00001583	WAGFLDEA00001583							
WAG-0287	3/22/2012	CII-CV Controlled Substances Mini Audit for Jupiter DC, Audit Period Dec 11 - Deb 12	WAGFLDEA00001830	WAGFLDEA00001853							
WAG-0288	3/22/2012	K. Kratofil email to District119RX re Pharmacy Diversion Awareness Conferenced	WAGFLDEA00000609	WAGFLDEA00000610							
WAG-0289	3/26/2012	H. Morrow email Consumer Relations	WAGFLDEA00000611	WAGFLDEA00000656							
WAG-0290	3/27/2012	Walgreens Ordering Frequency Calculation	WAGMDL00492397	WAGMDL00492399							
WAG-0291	3/29/2012	Pharmacy Manager 06775 email to K. Kratofil re Dr. Pham	WAGFLDEA00000657	WAGFLDEA00000657							
WAG-0292	4/2/2012	Handling Suspicious Drug Orders	WAGFLDEA00000027	WAGFLDEA00000027							
WAG-0293	4/2/2012	Handling Suspicious Orders and Loss of Controlled Drugs	WAGFLDEA00000028	WAGFLDEA00000028							
WAG-0294	4/2/2012	Walgreens Policy and Procedures re Customer Authentication	WAGFLDEA00001746	WAGFLDEA00001746							
WAG-0295	4/2/2012	K. Atwell to M. Rakauskas re Oxy 30mg	WAGFLDEA00001651	WAGFLDEA00001652							
WAG-0296	4/2/2012	K. Atwell email to M. Rakauskas re Store order changed quantity	WAGFLDEA00001653	WAGFLDEA00001654							
WAG-0297	4/5/2012	S. Wedekind email to D. Pinon re Per your request	WAGFLDEA00001688	WAGFLDEA00001691							
WAG-0298	4/6/2012	Walgreen pharmacies draw scrutiny in Florida by S. Hiaasen, The Miami Herald	WAGMDL_T1_TX00002770	WAGMDL_T1_TX00002773							
WAG-0299	4/10/2012	W. Burdick email to T. Gubbins re Ref 3664629 Executive Contact Owner Matt McLaughlin	WAGFLDEA00001692	WAGFLDEA00001695							
WAG-0300	4/17/2012	History of SOM Development	WAGMDL00657563	WAGMDL00657566							
WAG-0301	4/26/2012	DEA Suspicious Store Ordering Application Proposed Enhancement by W. Bancroft, Walgreens	WAGMDL00006622	WAGMDL00006627							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0302	4/26/2012	DEA Suspicious Store Ordering Application Proposed Enhancement by W. Bancroft, Walgreens	WAGMDL00007981	WAGMDL00007986							
WAG-0303	4/27/2012	Guide re Controlled Substance Pickup Policy	WAGFLDEA00000143	WAGFLDEA00000143							
WAG-0304	4/27/2012	Florida Controlled Substance ID Policy	WAGFLDEA00000174	WAGFLDEA00000175							
WAG-0305	4/30/2012	Policy of Theft or Diversion of Prescription Drugs by Walgreen Employee	WAGFLDEA00000328	WAGFLDEA00000328							
WAG-0306	4/30/2012	Funtional Requirements and (Macro) Design re Inventory Systems Development	WAGMDL00492402	WAGMDL00492416							
		Store Ordering									
WAG-0307	5/1/2012	Walgreens Business Requirements DEA Suspicious Ordering Phase IV	WAGMDL00492562	WAGMDL00492574							
WAG-0308	5/3/2012	DEA Reference Tools	WAGFLDEA00000157	WAGFLDEA00000157							
WAG-0309	5/3/2012	Dispensing Prescription Drugs Policy	WAGFLDEA00000161	WAGFLDEA00000161							
WAG-0310	5/3/2012	Guide re Review PDQ Order Quantities	WAGFLDEA00000276	WAGFLDEA00000276							
WAG-0311	5/4/2012	Letter from D. Weinstein to S. Langston re Administrative Subpoena No. GS-12 476915 to Walgreen Co., Jupiter Florida DC	WAGMDL00766460	WAGMDL00766461							
WAG-0312	5/7/2012	Suspicious Order Monitoring Process	WAGMDL00492575	WAGMDL00492579							
WAG-0313	5/9/2012	Order Sources and Status Controlled Drugs in Phase 3	WAGMDL00492580	WAGMDL00492580							
		Letter from D. Weinstein et al to S. Langston et al re Administrative Subpoena No. GS-12-476915	WAGMDL00766462	WAGMDL00766463							
WAG-0314	5/10/2012	Letter from A. Fisher et al to S. Langston et al re Walgreens Florid:	WAGMDL00766469	WAGMDL00766475							
WAG-0316	5/29/2012	Suspicious Drug Policy	WAGMDL00752212	WAGMDL00752213							
WAG-0317	06/00/2012	Focus on Compliance Survey, June 2012: Pain Management Prescription:	WAGMDL00767010	WAGMDL00767014							
WAG-0318	6/5/2012	Pharmacy Managers Email re Controlled Substance Order Quantity Override Process	WAGMDL00317093	WAGMDL00317094							
WAG-0319	6/6/2012	Walgreens Pharmacy and Health Care Code of Conduct and General Training	WAGMDL00444056	WAGMDL00444058							
WAG-0320	6/8/2012	Letter from D. Weinstein to S. Langston re Final Production for Administrative Subpoena No. GS-12-476915	WAGMDL00766477	WAGMDL00766479							
WAG-0321	6/11/2012	Controlled Substance Prescriptions & Good Faith Dispensing Policy	WAGMDL00008093	WAGMDL00008099							
WAG-0322	6/13/2012	Email from M. Blesser to P. Zagami et al re PPT for Tomorrow's 11:00 Meeting	WAGMDL00589674	WAGMDL00589679							
WAG-0323	6/18/2012	Walgreens DEA Intercept Suspicious Order	WAGMDL00492032	WAGMDL00492037							
WAG-0324	6/19/2012	Business Requirements re DEA Suspicious Ordering IV	WAGMDL00492581	WAGMDL00492584							
WAG-0325	6/25/2012	Email from F. Destefano to M. Bleser re Pharmaceutical Distribution and Dispensing Integrity	WAGMDL00589682	WAGMDL00589690							
WAG-0326	7/2/2012	Email from R. Stukel to J. Merritello et al re Discussion of Ceiling Limit	WAGMDL00077015	WAGMDL00077023							
WAG-0327	7/5/2012	Controlled Substances: Proposed Adjustment to the Aggregate Production Quotas for 2012, Federal Register	WAGMDL00766180	WAGMDL00766184							
WAG-0328	7/11/2012	Summary re Walgreens DEA Suspicious Store Ordering Application Proposed Enhancement	WAGMDL00609421	WAGMDL00609426							
WAG-0329	7/17/2012	Walgreen Co Controlled Substance Anti-Diversion & Compliance Program	WAGMDL00659828	WAGMDL00659856							
WAG-0330	7/18/2012	DOJ Statement of J. Rannazzisi re Responding to the Prescription Drug Abuse Epidemic									
WAG-0331	7/18/2012	Email from M. Mapes to D. Pinon re Suspicious Orders	WAGMDL00387635	WAGMDL00387637							
WAG-0332	7/23/2012	Letter from A. Fisher et al to S. Lawson et al re Administrative Subpoena No. GS-12-476915	WAGMDL00766480	WAGMDL00766490							
WAG-0333	8/3/2012	Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances, Federal Register	WAGMDL00766189	WAGMDL00766193							
WAG-0334	8/9/2012	Email from S. Mills to Anderson SAILCoordinator	WAGMDL00107532	WAGMDL00107533							
WAG-0335	8/9/2012	Controlled Substance Monitoring Phase 4	WAGMDL00371292	WAGMDL00371301							
WAG-0336	8/10/2012	Letter from A. Fisher et al to S. Lawson re Administrative Subpoena No. GS-12 476915	WAGMDL00766491	WAGMDL00766504							
WAG-0337	8/10/2012	Jack LeFrock v. Walgreen Co. Complaint and Exhibits, Summons to Walgreen	WAGMDL00768862	WAGMDL00768914							
WAG-0338	8/22/2012	Email from S. Mills to Murray re Controlled Substance Order Quantity Override Form	WAGMDL00107538	WAGMDL00107542							
WAG-0339	09/00/2012	Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings									
WAG-0340	9/10/2012	Controlled Substances: Final Adjusted Aggregate Production Quotas for 2012, Federal Register	WAGMDL00766185	WAGMDL00766188							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0341	9/16/2012	Email from R. Sloane to M. Blesser and F. Destefano re Update on Suspicious Ordering Monitoring	WAGMDL00528179	WAGMDL00528180							
WAG-0342	9/17/2012	Mills Email from S. Mills to D. Murray re Control Drug Adjustment:	WAGMDL00659076	WAGMDL00659078							
WAG-0343	9/26/2012	Business Requirements - Phase 5 Ceiling Calculation	WAGMDL00129432	WAGMDL00129436							
WAG-0344	9/26/2012	Business Requirements - Phase 5 Ceiling Calculation	WAGMDL00133969	WAGMDL00133973							
WAG-0345	9/27/2012	Walgreens Business Requirements - DEA Suspicious Ordering - Phase :	WAGMDL00491251	WAGMDL00491258							
WAG-0346	9/29/2012	Rx for Danger: Pain patients decry oxycodone shortage, but DEA says there isn't one by A. Pavuk, Orlando Sentinel	WAGMDL00766631	WAGMDL00766632							
WAG-0347	10/1/2012	Established Aggregate Production Quotas for Schedule I and II Controlled Substances, Federal Register	WAGMDL00766194	WAGMDL00766197							
WAG-0348	10/2/2012	DEA Suspicious Ordering - Phase 5	WAGMDL00395957	WAGMDL00395964							
WAG-0349	10/2/2012	Business Requirements - DEA Susp Ordering Phase 5 Store System:	WAGMDL00134013	WAGMDL00134020							
WAG-0350	10/2/2012	Letter from Rep. M. Amodei to M. Leonhart re DEA's Efforts to Confront Prescription Drug Abuse	WAGMDL00766624	WAGMDL00766625							
WAG-0351	10/5/2012	NCPA commends congressional request for clarification regarding DEA controlled substance enforcement by M. Johnsen, Drug Store News	WAGMDL00766633	WAGMDL00766634							
WAG-0352	10/9/2012	Email from R. Stukel to D. Murray and K. Provost re CSR Version Summary	WAGMDL00667936	WAGMDL00667943							
WAG-0353	10/16/2012	Email from S. Mills to WoodlandSAIL Coordinators	WAGMDL00107473	WAGMDL00107474							
WAG-0354	10/16/2012	Email from M. Federico to S. Mills re Walgreens #2865 DEA: BW4243426	WAGMDL00242055	WAGMDL00242057							
WAG-0355	10/16/2012	Letter from G. Werner to K. Chatmon re Dr. Stephen Stefano - Refusal to Fil	WAGMDL00768919	WAGMDL00768921							
WAG-0356	10/16/2012	Letter from G. Werner to K. Pearson re Dr. Stephen Stefano - Refusal to Fil	WAGMDL00768922	WAGMDL00768924							
WAG-0357	10/19/2012	Email from S. Mills to D. Murray re Controlled Substance Orders & SOM Event Procedures	WAGMDL00311410	WAGMDL00311410							
WAG-0358	10/19/2012	Email from T. Polster to M. Umbleby et al re HRP GFDP Documents with Recents Edits and Next Steps	WAGMDL00331004	WAGMDL00331030							
WAG-0359	10/19/2012	Form 10-K for the fiscal year ended August 31, 2012, Walgreen Co	WAGMDL_T1_TX00002774	WAGMDL_T1_TX00002806							
WAG-0360	11/8/2012	Offense Incident Report by Pasco Sheriff's	WAGMDL00768925	WAGMDL00768929							
WAG-0361	11/9/2012	Email from M. Bleser to D. Murray et al re November 8th DEA meeting at	WAGMDL00658246	WAGMDL00658248							
WAG-0362	11/14/2012	USDOJ DEA Knowing Your Customer/Suspicious Orders Reporting	WAGMDL00387625	WAGMDL00387628							
WAG-0363	11/15/2012	In re Walgreen Co. - Respondent's Prehearing Statement (USDOJ-DEA)	WAGMDL_T1_TX00002857	WAGMDL_T1_TX00002906							
WAG-0364	11/23/2012	Target Drug Good Faith Dispensing Policy	WAGMDL00289450	WAGMDL00289453							
WAG-0365	12/00/2012	Drug Trends Indianapolis, Indiana, DOJ J. Rannazzisi Slide Deck	WAGMDL00289068	WAGMDL00289178							
WAG-0366	12/4/2012	Email from S. Mills to K. Gehrand re Controlled Substance Order Quantity Override Form	WAGMDL00311235	WAGMDL00311236							
WAG-0367	12/6/2012	Email from S. Mills to S. McQueen Controlled Substance Order Quantity Override Form	WAGMDL00107162	WAGMDL00107163							
WAG-0368	12/7/2012	In re Walgreen Co. - Respondents' Supplemental Prehearing Statement (USDOJ DEA)	WAGMDL_T1_TX00002914	WAGMDL_T1_TX00002920							
WAG-0369	12/10/2012	Email from T. Polster to D. Murray re Whitepaper	WAGMDL00589739	WAGMDL00589742							
WAG-0370	12/31/2012	Email from J. Jones to Loss Prevention Operations re SIMS Enhancement for Controlled Substance Orders	WAGMDL00700240	WAGMDL00700241							
WAG-0371	12/31/2012	Ohio Office of Criminal Justice Services 2012 Semi-Annual Performance Report	SUMMIT_000108472	SUMMIT_000108480							
WAG-0372	00/00/2013	Drug Enforcement Administration History 2008-2013									
WAG-0373	00/00/2013	Clinical Pain Management Document	WAGMDL00303140	WAGMDL00303146							
WAG-0374	00/00/2013	Evolution of Controlled Substance Ordering Process	WAGMDL00395923	WAGMDL00395936							
WAG-0375	00/00/2013	DEA FY 2013 Performance Budget Congressional Submission	WAGMDL_T1_TX00002921	WAGMDL_T1_TX00003070							
WAG-0376	1/14/2013	Email from M. Chirica to M. Chirica et al re Appointment, Review Application Screens and Proposed Changes to Make Navigation Easier	WAGMDL00308327	WAGMDL00308349							
WAG-0377	1/14/2013	Email from C. Dymon to P. Daugherty re Process Flow Document	WAGMDL00303383	WAGMDL00303407							
WAG-0378	2/1/2013	Presentation re DEA Suspicious Store Ordering Application Enhancemen	WAGMDL00609410	WAGMDL00609418							
WAG-0379	2/8/2013	In re Walgreen Co. - Respondents' Supplemental Consolidated Prehearing Statement in the Pharmacy Matters (USDOJ-DEA)	WAGMDL_T1_TX00003142	WAGMDL_T1_TX00003161							
WAG-0380	2/12/2013	Email from S. Mills to W. Bancroft re New Oxy Ceiling Limit	WAGMDL00060670	WAGMDL00060674							
WAG-0381	2/14/2013	Memo from T. Polster to S. Mills re Status	WAGMDL00245769	WAGMDL00245769							
WAG-0382	2/15/2013	Letter from A. Fisher and P. Perry to C. Reeves and S. Lawson re Walgreens Perrysburg	WAGMDL00674277	WAGMDL00674279							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0383	2/16/2013	Email from R. Swords to K. Crawford re DEA Vegas Pilot	WAGMDL00066740	WAGMDL00066747							
WAG-0384	2/18/2013	Email from M. Chirica to A. Madarasz re Review Application Screens and Proposed Changes	WAGMDL00308329	WAGMDL00308329							
WAG-0385	2/20/2013	Letter from A. Fisher and P. Perry to C. Reeves and S. Lawson re Walgreens Perrysburg	WAGMDL00674280	WAGMDL00674281							
WAG-0386	2/21/2013	Email from S. Mills to PerrysburgC2SAIL re Controlled Substance Order Quantity Override Form	WAGMDL00415257	WAGMDL00415258							
WAG-0387	2/26/2013	Cleveland Police Department, Report 2/26/13, State of Ohio	CLEVE_004293491_1_0001	CLEVE_004293492_2_0001							
WAG-0388	2/27/2013	Requirements for DEA Phase 6	WAGMDL00491343	WAGMDL00491344							
WAG-0389	2/28/2013	Contents of Shipment from Walgreens Perrysburg DC to DEA	WAGMDL00709507	WAGMDL00709558							
WAG-0390	3/5/2013	Emails from S. Mills from J. Hernandez re Controlled Substance Order Immediate Action Required	WAGMDL00106996	WAGMDL00106998							
WAG-0391	3/11/2013	Email from S. Mills to E. Bratton re Oxy Timeline	WAGMDL00246016	WAGMDL00246016							
WAG-0392	3/15/2013	In re Walgreen Co. - Respondents' Consolidated Prehearing Statement in the #04391 and #03099 Pharmacy Matters (USDOJ-DEA)	WAGMDL_T1_TX00003214	WAGMDL_T1_TX00003265							
WAG-0393	3/19/2013	National Target Drug Good Faith Dispensing Checklis	WAGMDL00303132	WAGMDL00303132							
WAG-0394	3/21/2013	Oral Argument Hearing Transcript, Walgreen Company v. Drug Enforcement Administration	WAGMDL_T1_TX00003266	WAGMDL_T1_TX00003302							
WAG-0395	3/22/2013	Patient Internal Talking Points	WAGMDL00303133	WAGMDL00303138							
WAG-0396	3/22/2013	National Prescriber TD GFD Letter	WAGMDL00303139	WAGMDL00303139							
WAG-0397	3/22/2013	In re Walgreen Co. - Prehearing Statement in the #03836 Pharmacy Matter (USDOJ-DEA)	WAGMDL_T1_TX00003348	WAGMDL_T1_TX00003392							
WAG-0398	3/27/2013	Target Drug Good Faith Dispensing Policy	WAGMDL00289050	WAGMDL00289053							
WAG-0399	3/27/2013	National Target Drug Good Faith Dispensing Policy	WAGMDL00289054	WAGMDL00289057							
WAG-0400	3/27/2013	National Target Drug Good Faith Dispensing Policy	WAGMDL00289436	WAGMDL00289439							
WAG-0401	3/28/2013	Archived copy of DEA website "Knowing Your Customer/Suspicious Orders Reporting"	WAGMDL_T1_TX00003393	WAGMDL_T1_TX00003396							
WAG-0402	04/00/2013	Target Drug Good Faith Dispensing Slides	WAGMDL00303147	WAGMDL00303174							
WAG-0403	4/4/2013	Knowing Your Customer/Suspicious Orders Reporting US DOJ DEA Office of Diversion Control Website Printout	WAGMDL00770975	WAGMDL00770976							
WAG-0404	4/5/2013	In re Walgreen Co. - Respondent's Supplemental Consolidated Prehearing Statement in the #03836, #04391, and #03099 Pharmacy Matters (USDOJ-	WAGMDL_T1_TX00003409	WAGMDL_T1_TX00003420							
WAG-0405	4/8/2013	Email from S. Mills to J. Tolva re New Hire Doc:	WAGMDL00245867	WAGMDL00245920							
WAG-0406	4/8/2013	Email from S. Mills to J. Tolva re New Hire Docs:	WAGMDL00245867	WAGMDL00245877							
WAG-0407	4/18/2013	Email from M. Kelly to J. Jones et al re Walgreens Update	ENDO-OPIOID_MDL-01913038	ENDO-OPIOID_MDL-01913040							
WAG-0408	4/18/2013	Email from P. Weimer to C. AsburnYoder et al re Walgreens Update	ENDO-OPIOID_MDL-02861627	ENDO-OPIOID_MDL-02861629							
WAG-0409	4/18/2013	USDOJ DEA Knowing Your Customer/Suspicious Orders Reporting	WAGMDL00400365	WAGMDL00400366							
WAG-0410	4/25/2013	Email from C. Dymon to T. Polster et al re Feedback	WAGMDL00049632	WAGMDL00049633							
WAG-0411	5/15/2013	Letter from M. Grisham to R. Mazzoni re Policy Implementation by some Pharmacies in New Mexico	WAGMDL00691992	WAGMDL00691993							
WAG-0412	5/20/2013	Email from P. Daugherty to B. Sizemore re Questionable Prescriber Practice	WAGMDL00099892	WAGMDL00099895							
WAG-0413	06/00/2013	2013 Annual Meeting, Memorial Resolutions, C. E. Koop Introduced by New York, American Medical Association	WAGMDL_T1_TX00003421	WAGMDL_T1_TX00003477							
WAG-0414	6/13/2013	American Medical Association Organized Medical Staff Section 2013 Annual Meeting	WAGMDL_T1_TX00003478	WAGMDL_T1_TX00003525							
WAG-0415	6/13/2013	AMA Tells Pharmacists: "Don't Call Us We'll Call You", fdalawblog.ne	WAGMDL_T1_TX00003526	WAGMDL_T1_TX00003528							
WAG-0416	6/19/2013	Email from T. Polster to L. Mclean et al re Rx Integrity Team ad DEA Agreement	WAGMDL00316771; WAGMDL00316776	WAGMDL00316773; WAGMDL00316785							
WAG-0417	6/25/2013	Email from S. Mills to S. Diveney re Controlled Substance Order Quantity Override Form	WAGMDL00415194	WAGMDL00415195							
WAG-0418	7/1/2013	Pharmacists Warned on Intruding into Prescribing Decisions, American Medical News	WAGMDL_T1_TX00003529	WAGMDL_T1_TX00003530							
WAG-0419	08/00/2013	Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States	WAGMDL_T1_TX00003531	WAGMDL_T1_TX00003545							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0420	8/00/2013	Backlash Against Walgreens' Painkiller Crackdown, psychologytoday.com	WAGMDL_T1_TX00003546	WAGMDL_T1_TX00003548							
WAG-0421	8/1/2013	Controlled Substance Prescriptions & Good Faith Dispensing Policy	WAGMDL00008085	WAGMDL00008092							
WAG-0422	8/12/2013	Email from J. Howell to M. Ranick et al re Backlash Against Walgreen's New Painkiller Crackdown	WAGMDL00691989	WAGMDL00691991							
WAG-0423	9/13/2013	Memo from T. Polster to R. Swords re DEA Update Agenda	WAGMDL00575612	WAGMDL00575613							
WAG-0424	9/23/2013	Target Drug Good Faith Dispensing Policy	WAGMDL00008128	WAGMDL00008132							
WAG-0425	9/23/2013	Target Drug Good Faith Dispensing Policy	WAGMDL00289040	WAGMDL00289044							
WAG-0426	9/25/2013	Email from P. Daugherty to S. Mills re Ceiling Limits Tool & Controlled Substance Order Override Form	WAGMDL00306577	WAGMDL00306585							
WAG-0427	10/7/2013	Walgreens Authentication of Prescription Order Policy	WAGMDL00749381	WAGMDL00749407							
WAG-0428	12/10/2013	Powerpoint re Controlled Substance Order Review Business Logic	WAGMDL00624524	WAGMDL00624526							
WAG-0429	10/16/2013	Evolution of Controlled Substance Ordering Process	WAGMDL00658782	WAGMDL00658789							
WAG-0430	10/18/2013	Form 10-K for the fiscal year ended August 31, 2013, Walgreen Co	WAGMDL_T1_TX00003549	WAGMDL_T1_TX00003586							
WAG-0431	10/23/2013	Email from J. Rooney to P. Daugherty re Pictures	WAGMDL00302174	WAGMDL00302177							
WAG-0432	10/24/2013	Doctors to Pharmacists: Don't Call Us Slides	WAGMDL00306373	WAGMDL00306411							
WAG-0433	10/30/2013	Email from P. Daugherty to S. Mills re NASCSA Conference Notes and Store 10845 Visit	WAGMDL00306368	WAGMDL00306411							
WAG-0434	10/31/2013	Email from T. Polster to R. Swords re ABC Visii	WAGMDL00237263	WAGMDL00237264							
WAG-0435	11/8/2013	Email from M. Soder to P. Daugherty re GFD Concerns	WAGMDL00049160	WAGMDL00049161							
WAG-0436	11/16/2013	Akron Police Department Report of Investigation re D. Richardsor	SUMMIT_001520592	SUMMIT_001520596							
WAG-0437	11/18/2013	DI035P Items with Drug Class All NDC Match	WAGMDL00436802	WAGMDL00436802							
WAG-0438	11/19/2013	Email from G. Perry to P. Daugherty re Concern Regarding a Prescribe	WAGMDL00407144	WAGMDL00407145							
WAG-0439	12/4/2013	Powerpoint re Role of Tolerance vs. Ceiling	WAGMDL00624521	WAGMDL00624523							
WAG-0440	00/00/2014	DOJ DEA FY 2014 Performance Budget Congressional Submissior	WAGMDL_T1_TX00003587	WAGMDL_T1_TX00003720							
WAG-0441	2/21/2014	Controlled Substance Prescriptions & Good Faith Dispensing Policy	WAGMDL00008078	WAGMDL00008084							
WAG-0442	3/00/2014	Oxycodone, Drug Enforcement Administration, Office of Diversion Control, Drug & Chemical Evaluation Section	WAGMDL_T1_TX00003721	WAGMDL_T1_TX00003721							
WAG-0443	04/00/2014	Effects of Patient Medication Requests on Physician Prescribing Behavior: Results of a Factorial Experiment, McKinlay et al, National Institute of Health	WAGMDL_T1_TX00003722	WAGMDL_T1_TX00003736							
WAG-0444	4/17/2014	Memo from A. Patwardham to O'Donnell and O'Koren re Protocol for Recommending Naloxone	WAGMDL00095265	WAGMDL00095269							
WAG-0445	4/19/2014	Email from N. Polster to P. Daugherty re Naloxone	WAGMDL00095253	WAGMDL00095263							
WAG-0446	4/29/2014	Statement of J. Rannazzisi re Examining the Growing Problems of Prescripiton Drug and Heroin Abuse, Hearing Before the Subcommittee on Oversight and Investigations Committee on Energy and Commerce House of Representatives									
WAG-0447	5/12/2014	Email from E. Sharp to P. Daugherty re ABC Controlled Substances Threshold:	WAGMDL00047976	WAGMDL00047980							
WAG-0448	7/9/2014	Email from Pharmacy Manager to N. Pappos-Elledge re Prescriber Concer	WAGMDL00576457	WAGMDL00576457							
WAG-0449	7/14/2014	Email from RxIntegrity to P. Daugherty re 5138	WAGMDL00047953	WAGMDL00047956							
WAG-0450	9/18/2014	Email from P. Daugherty to M. Pallo re ABC CII Order OMP Over Thresholc	WAGMDL00305149	WAGMDL00305154							
WAG-0451	9/24/2014	Email from S. Mills to P. Daugherty re 7158 - Tramadol	WAGMDL00576348	WAGMDL00576352							
WAG-0452	9/25/2014	Suspicious Order Monitoring Program Policy and Procedures for the Pharmaceutical Integrity Team	WAGMDL00757776	WAGMDL00757784							
WAG-0453	11/19/2014	Pharmacists Using Tougher Guidelines to Curb Medication Misuse by S. Behnken, WFLA	WAGMDL_T1_TX00003737	WAGMDL_T1_TX00003737							
WAG-0454	12/12/2014	Memo from S. Gutt to A. Carter et al re Controlled Substance Order Monitoring Process Review	WAGMDL00674321	WAGMDL00674345							
WAG-0455	12/16/2014	RxIntegrity Website Tools & Reports as of December 16th, 2014	WAGMDL00015159	WAGMDL00015160							
WAG-0456	00/00/2015	H.R.471 Ensuring Patient Access and Effective Drug Enforcement Act of 2015, 114th Congress (2015-2016)	WAGMDL_T1_TX00003738	WAGMDL_T1_TX00003738							
WAG-0457	1/12/2015	The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction, Andrew Kolodny et al	WAGMDL_T1_TX00003739	WAGMDL_T1_TX00003759							
WAG-0458	1/22/2015	Email from E. Bratton to J. Tolva re Regarding Executive Contacts, Attachments: GFD epc Cases; GFD SF Cases	WAGMDL00018170	WAGMDL00018173							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0459	02/00/2015	Drug Shortages, Better Management of the Quota Process for Controlled Substances Need; Coordination between DEA and FDA Should be Improved, GAO	WAGMDL_T1_TX00003760	WAGMDL_T1_TX00003760							
WAG-0460	2/4/2015	Email from S. Mills to Pharmacy Manager 05331 re Potential Prescriber Issue	WAGMDL00309417	WAGMDL00309419							
WAG-0461	4/1/2015	Email from E. Stahmann to H. Accardo re Alleys Drug Pharmacy Snapshot	WAGMDL00406060	WAGMDL00406064							
WAG-0462	05/00/2015	Opioid Use in the Management of Diabetic Peripheral Neuropathy (DPN) in a Large Commercially Insured Population by P. Patil et al, Clin J Pain	WAGMDL_T1_TX00003761	WAGMDL_T1_TX00003774							
WAG-0463	5/1/2015	Letter from P. Kadzik to F. Upton re Responses to Questions for the Record Arising from J. Rannazzisi Appearance re Improving Predictability and Transparency in DEA and FDA Regulation, Hearing Before the Committee	WAGMDL_T1_TX00003775	WAGMDL_T1_TX00003791							
WAG-0464	5/1/2015	Rx Integrity District Manager Training, Walgreens Slide Decl	WAGMDL00006975	WAGMDL00007012							
WAG-0465	5/6/2015	DEA questioned on prescription problems at Senate hearing, WESH 2	WAGMDL_T1_TX00003792	WAGMDL_T1_TX00003794							
WAG-0466	5/21/2015	Email from S. Mills to S. Gutt et al re CSOKPI Test Results Summary	WAGMDL00039510	WAGMDL00039527							
WAG-0467	6/3/2015	Email from RxIntegrity to P. Daugherty re DR WITH OXY	WAGMDL00094759	WAGMDL00094760							
WAG-0468	6/17/2015	Diversion Investigators Manual	CAH_MDL2804_01483146	CAH_MDL2804_01483530							
WAG-0469	7/17/2015	Project Charter for Enhance CSOKPI App	WAGMDL00109238	WAGMDL00109245							
WAG-0470	9/3/2015	District 200 Hydrocodone Purchases Spreadsheet	WAGMDL00316594	WAGMDL00316594							
WAG-0471	9/3/2015	Audit spreadsheet	WAGMDL00316595	WAGMDL00316595							
WAG-0472	9/3/2015	Audit spreadsheet	WAGMDL00316596	WAGMDL00316596							
WAG-0473	9/3/2015	Audit spreadsheet	WAGMDL00316597	WAGMDL00316597							
WAG-0474	9/14/2015	Rx Integrity Process Summaries	WAGMDL00037074	WAGMDL00037075							
WAG-0475	9/15/2015	Masters Pharmaceuticals, Inc. Decision and Order									
WAG-0476	10/23/2015	Email from T. George to D. Luce re Pharmacy Ops&Care Committee and DEA Subcommittee Recap	WAGMDL00442094	WAGMDL00442097							
WAG-0477	10/26/2015	Email from RxIntegrity to P. Daugherty re Approved Controlled Substance Order for Store 14	WAGMDL00058489	WAGMDL00058492							
WAG-0478	10/28/2015	Form 10-K for the fiscal year ended August 31, 2015, Walgreens Boots Alliance Inc.									
WAG-0479	11/13/2015	Email from S. Mills to R. Baker re GFD Issue	WAGMDL00414785	WAGMDL00414787							
WAG-0480	12/8/2015	Rising Morbidity and Mortality in Midlife Among White Non-Hispanic Americans in the 21st Century by A. Case et al, PNAS	WAGMDL_T1_TX00003797	WAGMDL_T1_TX00003802							
WAG-0481	12/17/2015	Email from E. Stahmann to N. Polster re MOA Audit Document	WAGMDL00674282	WAGMDL00674306							
WAG-0482	00/00/2016	Between a Rock and a Hard Place: Can Physicians Prescribe Opioids to Treat Pain Adequately While Avoiding Legal Sanction by K. Dineen et al, AM J Law Justice Matter - ECU Open Case Form re S. Carr Deception to Obtain a	WAGMDL_T1_TX00003803	WAGMDL_T1_TX00003855							
WAG-0483	1/15/2016	Dangerous Drug	CUYAH_014632776	CUYAH_014632785							
WAG-0484	2/1/2016	Email from H. Hilker to P. Daugherty et al re Opioid Slide Review and Feedback for PSO	WAGMDL00001187	WAGMDL00001201							
WAG-0485	4/19/2016	Ensuring Patient Access and Effective Drug Enforcement Act of 2016, Public Law 114-115	WAGMDL_T1_TX00003856	WAGMDL_T1_TX00003859							
WAG-0486	5/3/2016	Report of NACDS Meeting with DEA	WAGMDL00502008	WAGMDL00502009							
WAG-0487	5/5/2016	Email from S. Mills to P. Daugherty re Controlled Substance Ordering	WAGMDL00104845	WAGMDL00104850							
WAG-0488	5/11/2016	Controlled Substance Prescriptions & Good Faith Dispensing Policy	WAGMDL00006890	WAGMDL00006896							
WAG-0489	6/29/2016	Target Drug Good Faith Dispensing Policy	WAGMDL00008119	WAGMDL00008123							
WAG-0490	6/29/2016	Target Drug Good Faith Dispensing Policy	WAGMDL00289031	WAGMDL00289035							
WAG-0491	7/7/2016	Walgreens SOP Flagged Order Review Process	WAGMDL00489370	WAGMDL00489371							
WAG-0492	7/11/2016	Email from S. Mills to E. Meeker et al re PSE Manual Orders Generated from Store	WAGMDL00044759	WAGMDL00044766							
WAG-0493	8/26/2016	Increases in Fentanyl-Related Overdose Deaths - Florida and Ohio, 2013-2015 by A. Peterson et al, Morbidity and Mortality Weekly Report, US Department of Health and Human Services/Centers for Disease Control and Prevention	WAGMDL_T1_TX00003860	WAGMDL_T1_TX00003865							
WAG-0494	09/00/2016	Prescription Drug Use and Misuse in the United States: Results from the 2015 National Survey on Drug Use and Health	WAGMDL_T1_TX00003866	WAGMDL_T1_TX00003913							
WAG-0495	9/14/2016	Email from N. Polster to T. George re CVS Pharmacists Must Check PMP Before Dispensing Opioids	WAGMDL00120533	WAGMDL00120538							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0496	10/20/2016	Email from E. Stahmann to Pharmacy Manager 03844 re Controlled Substance Ordering Immediate Action Required	WAGMDL00315494	WAGMDL00315496							
WAG-0497	00/00/2017	DEA FY 2017 Budget Request at a Glance	WAGMDL_T1_TX00003914	WAGMDL_T1_TX00003917							
WAG-0498	00/00/2017	Mortality and Morbidity in the 21st Century by A. Case et al, Brookings Papers on Economic Activity, Spring 2017	WAGMDL_T1_TX00003918	WAGMDL_T1_TX00003997							
WAG-0499	00/00/2017	A Nationwide Pharmacy Chain Responds to the Opioid Epidemic by E. Shafer et al., Journal of American Pharmacists Association	WAGMDL_T1_TX00003998	WAGMDL_T1_TX00004004							
WAG-0500	00/00/2017	Data Brief 329, Drug Overdose Deaths in the United States, 1999-2017, National Vital Statistics System, Mortality	WAGMDL_T1_TX00004005	WAGMDL_T1_TX00004008							
WAG-0501	00/00/2017	The National Survey on Drug Use and Health	WAGMDL_T1_TX00004009	WAGMDL_T1_TX00004061							
WAG-0502	1/12/2017	How People Obtain the Prescription Pain Relievers They Misuse	WAGMDL_T1_TX00004062	WAGMDL_T1_TX00004067							
WAG-0503	2/16/2017	Walgreens Commitment to Compliance	WAGMDL00254921	WAGMDL00254929							
WAG-0504	3/6/2017	National Target Drug Good Faith Dispensing Policy	WAGMDL00289026	WAGMDL00289030							
WAG-0505	3/6/2017	National Target Drug Good Faith Dispensing Policy	WAGMDL00289440	WAGMDL00289444							
WAG-0506	4/7/2017	Email from P. Daugherty to L. Linkenauer re Chronic Pain Treatment Centers of Frederick	WAGMDL00092961	WAGMDL00092964							
WAG-0507	4/13/2017	Email from RXM 04776 to P. Leonard re Dr. Lisy	AKRON_000367619	AKRON_000367619							
WAG-0508	5/5/2017	The Joint Commission's Pain Standards: Origins and Evolution	WAGMDL_T1_TX00004068	WAGMDL_T1_TX00004077							
WAG-0509	5/8/2017	Controlled Substance Prescriptions & Good Faith Dispensing Policy	WAGMDL00005359	WAGMDL00005365							
WAG-0510	5/12/2017	Spreadsheet re Denied Fills	WAGMDL00035542	WAGMDL00035542							
WAG-0511	6/30/2017	Masters Pharm., Inc. v. DEA, 861 F3d 206	WAGMDL_T1_TX00004078	WAGMDL_T1_TX00004092							
WAG-0512	7/17/2017	Email from P. Daugherty to R. Denton et al re Local Nurse Practitioner Inf	WAGMDL00409988	WAGMDL00409994							
WAG-0513	8/9/2017	Email from P. Daugherty to A. Kettlewell re SOV	WAGMDL00006645	WAGMDL00006652							
WAG-0514	8/10/2017	Email from P. Daugherty to N. Polster re Doctor and Good Faith	WAGMDL00238576	WAGMDL00238577							
WAG-0515	8/16/2017	Express Scripts to Limit Opioids Concerning Doctors, Associated Press	WAGMDL_T1_TX00004093	WAGMDL_T1_TX00004095							
WAG-0516	8/24/2017	Email from N. Polster to S. Gregory re DEA Drug Take-Back Regulation	WAGMDL00499183	WAGMDL00499187							
WAG-0517	9/5/2017	Prescription Opioid Use, Misuse, and Use Disorders in US Adults: 2015 National Survey on Drug Use and Health, Han et al., Annals of Internal Medicine, Vol 167, No. 5	WAGMDL_T1_TX00004096	WAGMDL_T1_TX00004105							
WAG-0518	10/1/2017	Target Drug Good Faith Dispensing Checklist, Walgreen	WAGMDL00005366	WAGMDL00005366							
WAG-0519	10/2/2017	Target Drug Good Faith Dispensing Policy, Walgreen	WAGMDL00005369	WAGMDL00005373							
WAG-0520	10/2/2017	National Target Drug Good Faith Dispensing Policy	WAGMDL00289045	WAGMDL00289049							
WAG-0521	10/17/2017	NACDS DEA Best Practice Forum Agenda	WAGMDL00421752	WAGMDL00421753							
WAG-0522	10/24/2017	Overdose Death Investigation and Prosecution Slides	HBC_MDL00009648	HBC_MDL00009649							
WAG-0523	10/25/2017	Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives - Hearing Before the Committee on Energy and Commerce House of Representatives	WAGMDL_T1_TX00004106	WAGMDL_T1_TX00004406							
WAG-0524	11/00/2017	Reports of Reference Committees 2017 Meeting of the American Medical Association House of Delegates	WAGMDL_T1_TX00004407	WAGMDL_T1_TX00004494							
WAG-0525	11/1/2017	Cancer Survivorship and Opioid Prescribing Rates: A Population-Based Matched Cohort Study Among Individuals With and Without a History of Cancer by R. Sutradhar et al, Cancer	WAGMDL_T1_TX00004495	WAGMDL_T1_TX00004502							
WAG-0526	00/00/2018	Ohio Automated Rx Reporting System, 2018 Annual Repor	WAGMDL_T1_TX00004503	WAGMDL_T1_TX00004515							
WAG-0527	00/00/2018	Origins of the Opioid Epidemic, Cardinal Health	WAGMDL_T1_TX00004516	WAGMDL_T1_TX00004519							
WAG-0528	00/00/2018	Report of the Board of Trustees (BOT Report 17-A-18) re Evaluating Actions by Pharmacy Benefits Manager and Payer Policies on Patient Care	WAGMDL_T1_TX00004520	WAGMDL_T1_TX00004528							
WAG-0529	02/00/2018	Opioid Crisis: No Easy Fix to Its Social and Economic Determinants by N. Dasgupta et al, AJPH Perspectives	WAGMDL_T1_TX00004529	WAGMDL_T1_TX00004533							
WAG-0530	2/8/2018	Methods, Trends and Solutions for Drug Diversion by T. Kristof, IAHSS Foundation	WAGMDL_T1_TX00004534	WAGMDL_T1_TX00004546							
WAG-0531	2/20/2018	The source and diversion of pharmaceutical drugs for non-medical use: A systematic review and meta-analysis	WAGMDL_T1_TX00004547	WAGMDL_T1_TX00004561							
WAG-0532	03/00/2018	How Good Intentions Contributed to Bad Outcomes: The Opioid Crisis by T. Rummans et al, Mayo Clinic Proceedings	WAGMDL_T1_TX00004562	WAGMDL_T1_TX00004568							
WAG-0533	3/6/2018	Proposed federal limits to opioid prescriptions draw opposition from physicians and patients by L. Facher, STAT News	WAGMDL_T1_TX00004569	WAGMDL_T1_TX00004572							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0534	3/30/2018	Email from J. Wood to N. Polster re Opioid Quantity Limit:	WAGMDL00252197	WAGMDL00252198							
WAG-0535	4/4/2018	Email from N. Polster to M. McLeod et al re Surgeon General Announcement	WAGMDL00010644	WAGMDL00010651							
WAG-0536	5/8/2018	Limiting Opioid Prescribing: The Fallout From Rules Telling Doctors How to Prescribe, Medscape	WAGMDL_T1_TX00004573	WAGMDL_T1_TX00004574							
WAG-0537	5/15/2018	Email from N. Polster to L. Badgley re Executive Summary Walmart 7 Day Opioid Policy	WAGMDL00315108	WAGMDL00315109							
WAG-0538	5/29/2018	Origins of an Epidemic: Purdue Pharma Knew Its Opioids Were Widely Abused by B. Meier, The New York Times	WAGMDL_T1_TX00004575	WAGMDL_T1_TX00004585							
WAG-0539	5/31/2018	Increased Use of Heroin as an Initiating Opioid of Abuse: Further Considerations and Policy Implications by T. Cicero et al, Addictive Behaviors	WAGMDL_T1_TX00004586	WAGMDL_T1_TX00004590							
WAG-0540	06/00/2018	IQVIA National Pharmacy Market Summary, Market Insights Report	WAGMDL_T1_TX00004591	WAGMDL_T1_TX00004594							
WAG-0541	6/00/2018	Target Drug Good Faith Dispensing Checklist	WAGMDL00000360	WAGMDL00000360							
WAG-0542	6/13/2018	Calendar Invite Email from L. Domenick to L. Domenick et al re Store #7832 Update	WAGMDL00042520	WAGMDL00042523							
WAG-0543	6/22/2018	Summit Omnibus Opposition to Motion to Dismiss:									
WAG-0544	7/25/2018	Email from N. Polster to S. Jonkman re Inform: Controlled Substances Block on Auto Refill	WAGMDL00740578	WAGMDL00740579							
WAG-0545	7/30/2018	Miami-Lukens' Responses to Plaintiffs' Combined Discovery Requests to Distributor Defendants									
WAG-0546	7/31/2018	ABCD's Objections and Responses to Plaintiffs' Combined Discovery Request									
WAG-0547	7/31/2018	Anda's Initial Response to Plaintiffs' Combined Discovery Requests to Distributor Defendants									
WAG-0548	7/31/2018	Cardinal Health's Objections and Responses to Plaintiffs' First Combined Discovery Requests									
WAG-0549	7/31/2018	H.D. Smith's Response to Plaintiffs' Combined Discovery Requests to Distributor Defendants									
WAG-0550	7/31/2018	McKesson's Objections and Responses to Plaintiffs' Combined Discovery Requests (Nos. 1-8)									
WAG-0551	7/31/2018	Schein's Objections and Responses to Plaintiff's Combined Discovery Request									
WAG-0552	8/9/2018	Clinicians Were Told their Patient Had Died of an Overdose. Then Prescribing Dropped by A. Joseph, STAT	WAGMDL_T1_TX00004595	WAGMDL_T1_TX00004598							
WAG-0553	8/10/2018	Opioid Prescribing Decreases After Learning of Patient's Fatal Overdose by J. Doctor et al, Science	WAGMDL_T1_TX00004599	WAGMDL_T1_TX00004602							
WAG-0554	8/31/2018	Business Requirements	WAGMDL00395937	WAGMDL00395956							
WAG-0555	9/7/2018	Results from the 2017 National Survey on Drug Use and Health: Detailed Tables, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality	WAGMDL_T1_TX00004603	WAGMDL_T1_TX00007473							
WAG-0556	9/7/2018	Results from the 2017 National Survey on Drug Use and Mental Health: Detailed Tables	WAGMDL_T1_TX00007474	WAGMDL_T1_TX00010344							
WAG-0557	9/20/2018	Cuyahoga County Court of Common Pleas Adult Probation Department, ORAS Pre-Sentencing Investigation re A. Burns	CUYAH_007488966	CUYAH_007488979							
WAG-0558	9/26/2018	Ceiling Override Report	WAGMDL00400358	WAGMDL00400358							
WAG-0559	9/27/2018	Prescription Supply's Objections and Responses to Plaintiffs' First Combined Discovery Requests									
WAG-0560	10/00/2018	Fentanyl, Drug Enforcement Administration, Office of Diversion Control, Drug & Chemical Evaluation Section	WAGMDL_T1_TX00010345	WAGMDL_T1_TX00010345							
WAG-0561	10/00/2018	Hydrocodone, DEA Diversion Control Division, Drug & Chemical Evaluation Section	WAGMDL_T1_TX00010346	WAGMDL_T1_TX00010346							
WAG-0562	10/1/2018	Flagged Order Report	WAGMDL00400360	WAGMDL00400360							
WAG-0563	10/1/2018	Functional Requirements and (Macro) Design	WAGMDL00400342	WAGMDL00400356							
WAG-0564	10/2/2018	Ceiling Limit Snapshot	WAGMDL00400359	WAGMDL00400359							
WAG-0565	10/3/2018	Defendants Walgreen Co. and Walgreen Eastern Co.'s Amended Objections and Responses to Plaintiffs' First Set of Interrogatories									
WAG-0566	10/11/2018	Form 10-K for the fiscal year ended August 31, 2018, Walgreens Boots Alliance, Inc.	WAGMDL_T1_TX00010347	WAGMDL_T1_TX00010497							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0567	10/11/2018	Form 10-K for the fiscal year ended August 31, 2018, Walgreens Boots Alliance Inc.	WAGMDL_T1_TX00010498	WAGMDL_T1_TX00010634							
WAG-0568	10/24/2018	Bellweather Plaintiffs Submission in Response to Discovery Ruling :									
WAG-0569	10/27/2018	Email from R. Khanna to K. Provost re DEA Business Reasor	WAGMDL00119542	WAGMDL00119548							
		NCHS Data Brief 329, Drug Overdose Deaths in the United States, 1999-2017 by H. Hedegaard et al, CDC National Center for Health Statistics									
WAG-0570	11/00/2018	ABDC's Supplemental Objections and Responses to Plaintiffs' Combined Discovery Requests	WAGMDL_T1_TX00010635	WAGMDL_T1_TX00010642							
WAG-0571	11/30/2018	Anda's Supplemental Response to Plaintiffs' First Combined Discovery Requests									
WAG-0572	11/30/2018	Cardinal Health's Supplemental Objections and Responses to Plaintiffs' First Combined Discovery Requests									
WAG-0573	11/30/2018	CVS' Amended Objections and Responses to Interrogatories No. 11, 13, and 30 of Plaintiffs' First Set of Interrogatories									
WAG-0574	11/30/2018	CVS' Objections and Responses to Plaintiffs' Combined Discovery Requests									
WAG-0575	11/30/2018	H. D. Smith's Supplemental Responses to Plaintiff's (First) Combined Discovery Requests									
WAG-0576	11/30/2018	HBC Service's Responses to Plaintiffs' (First) Set of Combined Discovery Requests									
WAG-0577	11/30/2018	Schein's First Amended Objections and Responses to Plaintiffs' (First) Combined Discovery Requests in Summit									
WAG-0578	11/30/2018	McKesson's Supplemental Objections and Responses to Plaintiffs' Combined Discovery Requests (Nos. 1-8)									
WAG-0579	11/30/2018	Prescription Supply's Amended Objections and Responses to Plaintiffs' First Combined Discovery Requests									
WAG-0580	11/30/2018	Rite Aid of Maryland's Objections and Responses to Track 1 Plaintiffs' First Set of Combined Discovery Requests									
WAG-0581	11/30/2018	Walmart's Responses to Plaintiffs (First) Combined Discovery Requests									
WAG-0582	11/30/2018	McKesson's Corrected Supplemental Objections and Responses to Plaintiffs' Combined Discovery Requests (Nos. 1-8)									
WAG-0583	12/6/2018	Defendants Walgreen Co. and Walgreen Eastern Co.'s Supplemental Responses to Plaintiffs (First) Combined Discovery Requests									
WAG-0584	12/21/2018	HBC Service's Amended Responses to Plaintiffs' (First) Set of Combined Discovery Requests									
WAG-0585	12/29/2018	NABP PMP Interconnect: The Only National Network of State-Based PMPs	WAGMDL_T1_TX00010643	WAGMDL_T1_TX00010648							
WAG-0586	00/00/2019	Legislature Establishes Foundation to Fund State PDMP Database, The Florida PDMP Foundation, Inc.	WAGMDL_T1_TX00010649	WAGMDL_T1_TX00010650							
WAG-0587	00/00/2019	Treating Pain Responsibly in the Midst of an Opioid Epidemic, Mayo Clinic	WAGMDL_T1_TX00010651	WAGMDL_T1_TX00010656							
WAG-0588	1/11/2019	Plaintiffs' Responses to Supplemental Interrogatory Issued in Discovery Ruling 12 to Plaintiffs									
WAG-0589	1/18/2019	Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses by S. Hadland et al, JAMA Network Open	WAGMDL_T1_TX00010657	WAGMDL_T1_TX00010668							
WAG-0590	1/18/2019	Study Links Drug Maker Gifts for Doctors to More Overdose Deaths by A. Goodnough, The New York Times	WAGMDL_T1_TX00010669	WAGMDL_T1_TX00010671							
WAG-0591	1/22/2019	Cardinal Health's Second Supplemental Objections and Responses to Plaintiffs' First Combined Discovery Requests									
WAG-0592	1/23/2019	Letter from R. Holt, Alaska Board of Pharmacy, to Pharmacies re Refusals to File	WAGMDL_T1_TX00010672	WAGMDL_T1_TX00010674							
WAG-0593	1/25/2019	Press Release from the State of Alaska re Urgent Notice: Pharmacies Urged to Consult Physician Before Refusing Their Patients' Opioid Prescription	WAGMDL_T1_TX00010675	WAGMDL_T1_TX00010676							
WAG-0594		Plaintiffs' Responses to the Amended and Clarified Discovery Ruling 12 Supplemental Interrogatory Issued to Plaintiffs', In Re National Prescription Opiate Litigation, Track One Cases									
WAG-0595	2/1/2019	Prescription Supply's Second Amended Objections and Responses to Plaintiffs' First Combined Discovery Requests									
WAG-0596	2/5/2019	Spreadsheet re ARCOS Data	WAGMDL00773926	WAGMDL00773926							
WAG-0597	2/6/2019	Alphabet's Verily Launches Opioid Treatment Nonprofit in Ohio, by E. Kincaid	WAGMDL_T1_TX00010677	WAGMDL_T1_TX00010679							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0599	2/6/2019	High-Tech Opioid Treatment Center Affiliated with Google to Open in Dayton by C. Schaefer, Fox 45 Now	WAGMDL_T1_TX00010680	WAGMDL_T1_TX00010682							
WAG-0600	2/6/2019	Five Things for Pharma Marketers to Know February 6, 2019 by A. Kanski, MM&M	WAGMDL_T1_TX00010683	WAGMDL_T1_TX00010685							
WAG-0601	2/6/2019	OneFifteen to Offer Comprehensive Model of Care to People with Opioid Use Disorder in Dayton, OH, OneFifteen	WAGMDL_T1_TX00010686	WAGMDL_T1_TX00010690							
WAG-0602	2/6/2019	Google Sister Company Looking to Partner on Opioid Rehab Campus in Ohio by B. Samuels, The Hill	WAGMDL_T1_TX00010691	WAGMDL_T1_TX00010692							
WAG-0603	2/6/2019	Verify to Build a High-Tech Rehab Center in Ohio to Address Opioid Epidemic by A. Chen, The Verge	WAGMDL_T1_TX00010693	WAGMDL_T1_TX00010696							
WAG-0604	2/6/2019	Alphabet is Taking on Health Care with a Bunch of Projects - Here are Some of the Most Ambitious by C. Farr	WAGMDL_T1_TX00010697	WAGMDL_T1_TX00010699							
WAG-0605	2/7/2019	Microsoft Healthcare Reveals More of its Strategy With New Cloud and AI Products for Hospitals, by J. Thorne	WAGMDL_T1_TX00010700	WAGMDL_T1_TX00010703							
WAG-0606	2/7/2019	With Google's Support, OneFifteen Creates Ecosystem for Opioid Treatment in Dayton, OH by S. Lubetkin	WAGMDL_T1_TX00010704	WAGMDL_T1_TX00010708							
WAG-0607	2/7/2019	Congressional Fallout and Agenda by D. Tahir, Politico	WAGMDL_T1_TX00010709	WAGMDL_T1_TX00010714							
WAG-0608	2/7/2019	Google-Affiliated Rehab Facility Set to Launch in Dayton by E. Fitzgerald, 2 News wdtv.com	WAGMDL_T1_TX00010715	WAGMDL_T1_TX00010716							
WAG-0609	2/13/2019	HBC Service's Second Amended Responses to Plaintiffs' (First) Set of Combined Discovery Requests									
WAG-0610	2/14/2019	Fentanyl Deaths from Mexican Oxy Pills Hit Arizona Hard by Associated Press	WAGMDL_T1_TX00010717	WAGMDL_T1_TX00010720							
WAG-0611	2/19/2019	Defendants Walgreen Co. and Walgreen Eastern Co.'s Second Supplemental Responses to Plaintiffs' (First) Combined Discovery Requests									
WAG-0612	3/4/2019	ABDC's Second Supplemental Objections and Responses to Plaintiffs' Combined Discovery Requests									
WAG-0613	3/4/2019	Cardinal Health's Third Supplemental Objections and Responses to Plaintiffs' First Combined Discovery Requests									
WAG-0614	3/4/2019	McKesson's Second Supplemental Objections and Responses to Plaintiffs' Combined Discovery Requests (Nos. 1-8)									
WAG-0615	3/21/2019	Summit County v Purdue et al - Third Amended Complaint									
WAG-0616	3/21/2019	Cuyahoga Cty Complaint - Third Amended Complaint									
WAG-0617	3/29/2019	McKesson's Third Supplemental Objections and Responses to Plaintiffs' Combined Discovery Requests									
WAG-0618	04/00/2019	Connecting State Prescription Monitoring Programs Nationwide, NABP PMP InterConnect	WAGMDL_T1_TX00010721	WAGMDL_T1_TX00010721							
WAG-0619	4/12/2019	Letter from A. Dustin, Dept of Justice, to L. Singer re Touhy Authorization re Rafalski	WAGMDL_T1_TX00010722	WAGMDL_T1_TX00010724							
WAG-0620	4/12/2019	Anda's Third Supplemental Response to Plaintiffs' (First) Combined Discovery Requests									
WAG-0621	5/10/2019	Appendix C - McCann Flag Initial Transaction:									
WAG-0622	5/10/2019	Appendix C - McCann Flag Method Examples									
WAG-0623	5/10/2019	Appendix C - McCann Flagging Methodology - Example Flagging.twb									
WAG-0624	5/10/2019	Appendix C - McCann Flagging Methodology - Flag First Txn.twb									
WAG-0625	5/10/2019	Appendix C - McCann Identified Transactions.csv									
WAG-0626	5/10/2019	Appendix D - Allegedly Suspicious Order Analysis - Dataset, Spreadsheets									
WAG-0627	5/10/2019	Appendix D - Allegedly Suspicious Order Analysis - Full Time Period .twb;									
WAG-0628	5/10/2019	Allegedly Suspicious Order Analysis - Restricted Time Period .twb:									
WAG-0629	5/10/2019	Appendix D - Allegedly Suspicious Order Analysis									
WAG-0630	5/10/2019	Appendix E - Old Store and New Store Analysis									
WAG-0631	5/10/2019	Appendix E - Old Stores vs. New Stores - Flagging - Dataset, Spreadsheets									
WAG-0632	5/10/2019	Appendix E - Old Stores vs. New Stores - Flagging.twb:									
WAG-0633	5/10/2019	Appendix E - Volume Differences Old Stores vs New Stores - Dataset, Spreadsheet									
WAG-0634	5/10/2019	Appendix E - Volume Differences Old Stores vs New Stores.twb:									
WAG-0635	5/10/2019	Appendix F - Refused Buyer DEA Number:									

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Not Offered Admitted		
WAG-0636	5/10/2019	Appendix F Reused Buyer DEA Numbers, Appendix H Monthly Transaction Summary.twbx									
WAG-0637	5/10/2019	Appendix F Reused Buyer DEA Numbers, Appendix H Monthly Transaction Summary, Spreadsheet									
WAG-0638	5/10/2019	Appendix G - Drug Strength Charts- Dataset, Spreadsheet									
WAG-0639	5/10/2019	Appendix G - Drug Strength Charts									
WAG-0640	5/10/2019	Appendix G - Drug Strength Charts.twbx									
WAG-0641	5/10/2019	Appendix H - Monthly Transaction Summary Charts by Store									
WAG-0642	5/10/2019	Gregory Anderson Curriculum Vitae									
WAG-0643	5/10/2019	Laurence Baker Curriculum Vitae									
WAG-0644	5/10/2019	Robert Brunner Curriculum Vitae									
WAG-0645	5/10/2019	Robert Parrado Curriculum Vitae									
WAG-0646	5/14/2019	Opioid Misuse Initiation: Implications for Intervention by K. Rigg et al, Journal of Addictive Diseases	WAGMDL_T1_TX00010725	WAGMDL_T1_TX00010737							
WAG-0647	06/00/2019	National Institute on Drug Abuse - Drug Facts on Heroin	WAGMDL_T1_TX00010738	WAGMDL_T1_TX00010744							
WAG-0648	6/24/2019	Walgreens Implements Safe Drug Disposal Options for Customers in All of Its Pharmacies, Walgreens Newsroom	WAGMDL_T1_TX00010745	WAGMDL_T1_TX00010746							
WAG-0649	6/24/2019	Walgreens to Provide Drug Disposal Packets Free to Customers by Associated Press, The Washington Post	WAGMDL_T1_TX00010747	WAGMDL_T1_TX00010748							
WAG-0650	07/00/2019	Buprenorphine, DEA Diversion Control Division, Drug & Chemical Evaluation Section	WAGMDL_T1_TX00010749	WAGMDL_T1_TX00010749							
WAG-0651	07/00/2019	Methadone, DEA Diversion Control Division, Drug & Chemical Evaluation Section	WAGMDL_T1_TX00010750	WAGMDL_T1_TX00010750							
WAG-0652	8/5/2019	J. Stein letter to N. Pelosi re opioid epidemic	WAGMDL_T1_TX00010751	WAGMDL_T1_TX00010756							
WAG-0653	8/12/2019	As overdoses soared, nearly 35 billion opioids - half of distributed pills - handled by 15 percent of pharmacies by J. Abelson et al, The Washington Post	WAGMDL_T1_TX00010757	WAGMDL_T1_TX00010762							
WAG-0654	8/12/2019	As overdoses soared, nearly 35 billion opioids - half of distributed pills - handled by 15 percent of pharmacies by J. Abelson et al, The Washington Post	WAGMDL_T1_TX00010763	WAGMDL_T1_TX00010777							
WAG-0655	8/12/2019	How many pain pills went to your pharmacy? By A. Emandjomeh et al, The Washington Post	WAGMDL_T1_TX00010778	WAGMDL_T1_TX00010787							
WAG-0656	11/18/2019	Discount Drug Mart's Amended Responses to Plaintiffs' Combined Discovery Requests									
WAG-0657	9/27/2012	Email from M. Umbleby to T. Polster re PDQ Email	WAGMDL00113825	WAGMDL00113826							
WAG-0658	4/11/2013	Email from E. Svihra to Loss Prevention Operations re Transferring Controlled Substances	WAGMDL00700161	WAGMDL00700161							
WAG-0659	5/19/2015	WESH 2 Gets Answers on State's Prescription Problems, WESH	WAGMDL_T1_TX00003795	WAGMDL_T1_TX00003796							
WAG-0660	00/00/0000	Map Screenshots - New and Old Stores Together									
WAG-0661	00/00/0000	Map Screenshots - New Stores									
WAG-0662	00/00/0000	Map Screenshots - Old Stores									
WAG-0663	00/00/0000	Opioid Overdose Data Resources CDC Injury Center	WAGMDL_T1_TX00000001	WAGMDL_T1_TX00000003							
WAG-0664	00/00/0000	Walgreens Stores in Cuyahoga and Summit, OH by McCann Flagging Methodology by First Fail Date									
WAG-0665	00/00/0000	National Drug Code Directory_ndcfile.txt									
WAG-0666	00/00/0000	SQL_readme.txt									
WAG-0667	00/00/0000	Tableau_readme.txt									
WAG-0668	00/00/0000	Walgreens Store Location Information									
WAG-0669	00/00/0000	Excessive Purchases Schedule II; Excessive Purchases Schedule III, IV, V, FOIA Confidential Treatment Requested by Cardinal	CAH_MDL_PRIORPROD_DE A07_01384160-R	CAH_MDL_PRIORPROD_DE A07_01384161-R							
WAG-0670	00/00/0000	Pharmacies Limit Legitimate Paid Meds, Health News Florida Staff	WAGMDL_T1_TX00000004	WAGMDL_T1_TX00000005							
WAG-0671	00/00/0000	Drugs @ FDA: FDA Approved Drug Products, Endo Pharma New Drug Application 007337 Percodan, FDA	WAGMDL_T1_TX00000006	WAGMDL_T1_TX00000007							
WAG-0672	00/00/0000	Drugs @ FDA: FDA Approved Drug Products, Hospira New Drug Application 016194 Talwin, FDA	WAGMDL_T1_TX00000008	WAGMDL_T1_TX00000008							
WAG-0673	00/00/0000	Drugs @ FDA: FDA Approved Drug Products Vintage Pharma LLC Abbreviated New Drug Application 085106 Percocet, FDA	WAGMDL_T1_TX00000009	WAGMDL_T1_TX00000009							
WAG-0674	00/00/0000	24 Hour Walgreens Pharmacy - Katy, TX Store Location Information Printout	WAGMDL_T1_TX00000010	WAGMDL_T1_TX00000012							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Not		
									Offered	Admitted	Admitted
WAG-0675	00/00/0000	Knowing Your Customer/Suspicious Orders Reporting, US DOJ DEA Diversion Control Division	WAGMDL_T1_TX00000013	WAGMDL_T1_TX00000014							
WAG-0676	00/00/0000	24 Hours Walgreens Pharmacy - Lorain, OH Store Location Information	WAGMDL_T1_TX00000015	WAGMDL_T1_TX00000017							
WAG-0677	00/00/0000	Walgreens Pharmacy - New Port Richey, FL Store Location Information	WAGMDL_T1_TX00000018	WAGMDL_T1_TX00000020							
WAG-0678	00/00/0000	Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factor	WAGMDL_T1_TX00000021	WAGMDL_T1_TX00000022							
WAG-0679	00/00/0000	Walgreens Pharmacy - Palm Harbor, FL Store Location Information	WAGMDL_T1_TX00000023	WAGMDL_T1_TX00000024							
WAG-0680	00/00/0000	DEA Drug Scheduling, Printout from DEA Website	WAGMDL_T1_TX00000025	WAGMDL_T1_TX00000027							
WAG-0681	00/00/0000	Automation of Reports and Consolidated Orders System (ARCOS), US DOJ DEA Diversion Control Division	WAGMDL_T1_TX00000028	WAGMDL_T1_TX00000029							
WAG-0682	00/00/0000	Registration Categories and Fees, US DOJ DEA Diversion Control Division	WAGMDL_T1_TX00000030	WAGMDL_T1_TX00000031							
WAG-0683	00/00/0000	ARCOS Registration Handbook, Part I General Information, US DOJ DEA Diversion Control Division Website	WAGMDL_T1_TX00000032	WAGMDL_T1_TX00000034							
WAG-0684	00/00/0000	Controlled Substance Schedules, US DOJ DEA Diversion Control Division Website	WAGMDL_T1_TX00000035	WAGMDL_T1_TX00000037							
WAG-0685	00/00/0000	Quota Applications, US DOJ DEA Diversion Control Division Website	WAGMDL_T1_TX00000038	WAGMDL_T1_TX00000039							
WAG-0686	00/00/0000	Theft/Loss Reporting; US DOJ DEA Diversion Control Division	WAGMDL_T1_TX00000040	WAGMDL_T1_TX00000041							
WAG-0687	00/00/0000	Target Drug Good Faith Dispensing Policy	WAGMDL00289036	WAGMDL00289039							
WAG-0688	00/00/0000	Summary of Requirements DEA Diversion Control Fee Account	WAGMDL_T1_TX00000042	WAGMDL_T1_TX00000054							
WAG-0689	00/00/0000	Draft notes re Handling Suspicious Orders	WAGFLDEA00001856	WAGFLDEA00001857							
WAG-0690	00/00/0000	Presentation re Good Faith Dispensing	WAGFLDEA0000184	WAGFLDEA0000205							
WAG-0691	00/00/0000	Store Sales and Safety Concerns Report	WAGFLDEA00001710	WAGFLDEA00001710							
WAG-0692	00/00/0000	A Pharmacist's Guide to Prescription Fraud, DEA Informational Brochure	WAGMDL00766620	WAGMDL00766621							
WAG-0693	00/00/0000	Prescriber Due Diligence Review Form	WAGMDL00767034	WAGMDL00767037							
WAG-0694	00/00/0000	Distribution of Suspicious Order Reports	WAGMDL00768935	WAGMDL00768936							
WAG-0695	00/00/0000	Office of Chief Counsel Diversion and Regulatory Litigation by C. Mendez Slides Deck	WAGMDL00768986	WAGMDL00769008							
WAG-0696	00/00/0000	Suspicious Order Reports (SORs)	WAGMDL00390035; WAGMDL00396034	WAGMDL00395922; WAGMDL00400341							
WAG-0697	4/29/2008	Cleveland Police Department, Report 4/29/08, State of Ohio	CLEVE_004084191	CLEVE_004084290							
WAG-0698	10/20/2008	Cleveland Police Department, Report 10/20/08, State of Ohio	CLEVE_004085959	CLEVE_004086058							
WAG-0699	11/19/2009	Cleveland Police Department, Report 11/19/09, State of Ohio	CLEVE_004086259	CLEVE_004086358							
WAG-0700	4/14/2011	Cleveland Police Department, Report 4/14/11, State of Ohio	CLEVE_004084691	CLEVE_004084758							
WAG-0701	5/15/2011	Cleveland Police Department, Report 11/19/09, State of Ohio	CLEVE_004086359	CLEVE_004086458							
WAG-0702	12/2/2011	Cleveland Police Department, Report 12/2/11, State of Ohio	CLEVE_004084759	CLEVE_004084858							
WAG-0703	1/23/2012	Cleveland Police Department, Report 1/23/12, State of Ohio	CLEVE_004085359	CLEVE_004085458							
WAG-0704	3/26/2012	Cleveland Police Department, Report 3/26/12, State of Ohio	CLEVE_004086159	CLEVE_004086258							
WAG-0705	4/18/2012	Cleveland Police Department, Report 4/18/12, State of Ohio	CLEVE_004085659	CLEVE_004085758							
WAG-0706	7/20/2012	Cleveland Police Department, Report 7/20/12, State of Ohio	CLEVE_004085059	CLEVE_004085158							
WAG-0707	9/5/2012	Cleveland Police Department, Report 9/5/12, State of Ohio	CLEVE_004085459	CLEVE_004085558							
WAG-0708	10/16/2012	Cleveland Police Department, Report 8/31/18, State of Ohio	CLEVE_004086759	CLEVE_004086858							
WAG-0709	1/11/2013	Cleveland Police Department, Report 1/11/13, State of Ohio	CLEVE_004085159	CLEVE_004085258							
WAG-0710	12/6/2013	Cleveland Police Department, Report 12/6/13, State of Ohio	CLEVE_004085759	CLEVE_004085858							
WAG-0711	12/17/2013	Cleveland Police Department, Report 12/17/13, State of Ohio	CLEVE_004083691	CLEVE_004083790							
WAG-0712	12/18/2013	Cleveland Police Department, Report 12/18/13, State of Ohio	CLEVE_004083791	CLEVE_004083890							
WAG-0713	5/6/2014	Cleveland Police Department, Report 5/6/13, State of Ohio	CLEVE_004083891	CLEVE_004083990							
WAG-0714	9/16/2014	Cleveland Police Department, Report 9/16/14, State of Ohio	CLEVE_004086459	CLEVE_004086558							
WAG-0715	4/15/2015	Cleveland Police Department, Report 4/15/15, State of Ohio	CLEVE_004084291	CLEVE_004084390							
WAG-0716	10/1/2015	Cleveland Police Department, Report 10/1/15, State of Ohio	CLEVE_004085259	CLEVE_004085358							
WAG-0717	3/23/2016	Cleveland Police Department, Report 3/23/16, State of Ohio	CLEVE_004084391	CLEVE_004084490							
WAG-0718	8/31/2018	Cleveland Police Department, Report 8/31/18, State of Ohio	CLEVE_004086559	CLEVE_004086658							
WAG-0719	8/30/2019	Changes in Opioid-Involved Overdoses Deaths by Opioid Type and Presence of Benzodiazepines, Cocaine, and Methamphetamine - 25 States, July-December 2017 to January-June 2018, CDC Morbidity and Mortality Weekly Report	WAGMDL_T1_TX00010788	WAGMDL_T1_TX00010795							
WAG-0720	9/20/2019	Flailing on Fentanyl, K. Zezima & C. Itkowitz, The Washington Post	WAGMDL_T1_TX00010796	WAGMDL_T1_TX00010835							
WAG-0721	3/13/2019	The Fentanyl Failure, S. Higham, et al., The Washington Post	WAGMDL_T1_TX00010836	WAGMDL_T1_TX00010873							

Ex. No.	Date	Description	Beg Bates	End Bates	901 Stip.	Admission Stip.	Plaintiff Objections	Defendants' Objections	Offered	Admitted	Not Admitted
WAG-0722	8/23/2019	The flow of the fentanyl: In the Mail, over the border, S. Horwitz & S. Higham, The Washington Post	WAGMDL_T1_TX00010874	WAGMDL_T1_TX00010910							
WAG-0723	5/8/2018	Combating the Opioid Epidemic: Examining Concerns About Distribution and Diversion, House of Representatives, Subcommittee on Oversight and Investigations, Committee on Energy and Commerce Report	WAGMDL_T1_TX00010911	WAGMDL_T1_TX00011040							

CERTIFICATE OF SERVICE

I hereby certify that on this 25th day of September, 2019, a notice of the foregoing has been served via CM/ECF to all counsel of record. Pursuant to Civil Jury Trial Order, ECF No. 1598, copies have also been emailed to chambers in Word, WordPerfect, and Excel format.

/s/ Kaspar J. Stoffelmayr
Kaspar J. Stoffelmayr

*Counsel for Walgreen Co. and Walgreen
Eastern Co.*